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1.  ABBREVIATIONS   
5-Aza  5-Azacytidine  
α-actinin Alpha actinin, sarcomeric 
α-SMA Alpha smooth muscle actin 
AA  Ascorbic acid  
AHT  Adult heart tissue  
BSA  Bovine serum albumin  
CRM   Cardiac reprogramming medium  
CDM   Cardiac differentiation medium 
cDNA   Complimentary deoxyribonucleic acid  
cECM   Cardiac extracellular matrix 
CFs  Cardiac fibroblasts  
CMs  Cardiomyocytes  
CPCs   Cardiac progenitor cells  
cTnT  Cardiac troponin  
CY5  Cyanine 5 
DELC  Delivery control  
DM   Differentiation medium  
DMEM Dulbecco’s Modified Eagle Medium  
DNA   Deoxyribonucleic acid  
eGFP   Enhanced green fluorescent protein 
ECM  Extracellular matrix  
EF   Ejection Fraction 
ESCs   Embryonic stem cells 
FACS  Fluorescence activated cell sorting 
FBS  Fetal bovine serum  
FCS   Fetal calf serum  
Gata4   GATA binding protein 4 
GFP  Green fluorescence protein 
GMTMy Gata4, Mef2c, Tbx5, Myocd 
GO   Gene ontology 
G418  Geneticin Antibiotic 




HI-FBS Heat-inactivated fetal bovine serum 
HL1  HL1 cardiac muscle cell line  
HT1080 Human fibrosarcoma cell line  
ICC   Immunocytochemistry  
iCMPs  Induced cardiomyocyte precursors  
iPSCs  Induced pluripotent stem cells 
IRES  Internal ribosome entry site 
LeV   Lentivirus  
LV   Left Ventricle 
MBs  Molecular Beacons 
mEH   Mouse embryonic heart  
Mef2a  Myocyte-specific enhancer factor 2a 
Mef2c  Myocyte-specific enhancer factor 2c 
MI   Myocardial infarction 
mNH   Mouse neonatal heart  
MOI  Multiplicity of infection  
MYH6  Myosin heavy chain 6, cardiac muscle alpha (αMHC) 
MYH7  Myosin heavy chain 7, cardiac muscle beta (βMHC) 
MYH6/7 Myosin heavy chain 6/7 (α/βMHC) 
Myocd  Myocardin  
NEGC  Negative control  
PCR  Polymerase chain reaction  
PEI  Polyethylenimine  
RNA  Ribonucleic acid 
RNA-Seq RNA sequencing 
RT  Room temperature  
SFDM  Serum free differentiation medium  
SFFV  Spleen focus forming virus  
Tbx5  T-box transcription factor 5 
TNNT2  Troponin T 








2. ABSTRACT  
 
Cardiovascular diseases are the leading cause of death globally. Cardiomyocytes (CMs) have poor 
proliferative capacity, and the therapeutic options to restore heart function are limited. However, 
there are several promising strategies for cardiac regeneration. The most promising approach is 
cell transplantation therapy using newly generated CMs. Induced cardiomyocytes (iCMs) 
generated from cardiac fibroblasts (CFs) represent a potential cell population. However, the iCM 
reprogramming efficiency is low and mature iCMs do not proliferate. Here I report the generation 
of proliferative iCM precursor cells (iCMPs) with CM lineage commitment by genetic 
reprogramming.  
 
CFs were reprogrammed into iCMPs via transduction with cardiomyogenesis-related transcription 
factors Gata4, Mef2c, Tbx5 and Myocd.  Global transcriptome profiling of iCMPs, CFs and mouse 
adult CMs was performed by RNA sequencing. For differentiation into iCMs, the effectiveness of 
previously established differentiation conditions was tested. I then extended the approach to the 
native heart environment. The therapeutic potential of iCMPs was evaluated in a in a rodent model 
of ischemic heart disease. 
 
iCMPs expressed α-actinin, cTnT and myosin protein as observed by immunocytology. The 
iCMPs were a heterogenous population of cTnT positive cells, most of which showed a round 
epithelial like cells morphology. These iCMPs could robustly proliferative and when 
supplemented with ascorbic acid could maintain a stable phenotype. Pure populations of iCMPs 
were obtained by transcriptional selection with Myh6/7-targeting molecular beacons. Maturation 
studies showed that iCMPs displayed elongated sarcomere-like structures after stimulation with 5-
Azacytidine a general demethylating agent, which has previously been described for 
differentiation toward cardiomyocytes. Gene expression pattern suggests that these iCMPs 
displayed a unique gene expression profile that move towards CM development. In addition, when 
transplanted into rodent hearts following myocardial infarction (MI), they show improved cardiac 




In conclusion I can transdifferentiate fibroblasts into cardiomyogenic cells that can be purified 
using a clinically compatible molecular beacon technique, can be expanded to yield therapeutic 
cell doses and exert therapeutic benefits.   
 
















Herz-Kreislauf-Erkrankungen sind weltweit die häufigste Todesursache. Kardiomyozyten (CMs) 
haben eine geringe Proliferationskapazität und die therapeutischen Möglichkeiten zur 
Wiederherstellung der Herzfunktion sind begrenzt. Der wohl vielversprechendste Ansatz zur 
Herzregeneration ist die Transplantation von CMs. Eine mögliche Zielpopulation sind induzierte 
Kardiomyozyten (iCMs), die aus Herzfibroblasten (CFs) erzeugt werden. Allerdings ist die 
Effizienz der iCM-Reprogrammierung gering und reife iCMs sind nicht in der Lage, sich zu 
vermehren. Eine Lösung dieses Problems ist gleichfalls das Ziel der vorliegenden Arbeit: die 
Erzeugung proliferativer iCM-Vorläuferzellen (iCMPs) mit CM-Abstammung durch genetische 
Reprogrammierung. 
 
CFs wurden durch Transduktion verschiedener Transkriptionsfaktoren, die im Zusammenhang mit 
der Kardiomyogenese stehen, beispielsweise Gata4, Mef2c, Tbx5 und Myocd, in iCMPs 
umprogrammiert. Die Untersuchung des Transkriptoms erfolgte durch RNA-Sequenzierung. 
Weiterhin wurde die Effizienz bereits etablierter Kultivierungsbedingungen bezüglich der 
Differenzierung dieser Zellen in CMs untersucht. Dieser Ansatz wurde anschließend auf die native 
Herzumgebung ausgedehnt. Schließlich wurde das therapeutische Potenzial von iCMPs in einem 
Nagetiermodell für ischämische Herzerkrankungen bewertet. 
 
Immunzytologische Untersuchungen zeigten, dass die generierten iCMPs α-Actinin und Myosin 
exprimieren. Sie stellen eine heterogene Population von cTnT-positiven Zellen dar, von denen die 
meisten eine kreisförmige epitheliale Zellmorphologie aufwiesen. Sie waren in der Lage, sich zu 
vermehren und unter Zugabe von Ascorbinsäure wiesen sie einen stabilen Phänotyp auf. Nach 
Transkriptionsselektion mit Myh6/7-abzielender molecular beacons wurde eine reine Population 
an iCMPs gewonnen. Reifungsstudien zeigten, dass iCMPs nach Stimulation mit 5-Azacytidin 
verlängerte sarkomerartige Strukturen haben. Zudem legt das Genexpressionsmuster nahe, dass 
diese iCMPs ein einzigartiges Genexpressionsprofil besitzen. Wurden sie nach einem 
Myokardinfarkt (MI) in Nagetierherzen transplantiert, übten sie darüber hinaus therapeutische 





Zusammenfassend war es möglich, Fibroblasten in kardiomyogene Zellen zu transdifferenzieren 
und sie unter Verwendung einer klinisch kompatiblen molecular beacon-Technik zu isolieren. 
Anschließend wurden sie kultiviert, um therapeutische Zelldosen zu erzielen und therapeutische 
Vorteile, wie eine verbesserte Herzfunktion, zu ermöglichen.  
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5. INTRODUCTION  
 
5.1. HEART FAILURE  
 
Heart failure is the ultimate fate of many patients with various forms of heart disease. One of the 
major underlying causes is the irreversible loss of cardiomyocytes (CMs). After heart injury, 
myocardial infarction or chronic inflammation, deleterious remodeling of the heart wall ensues, 
which leads to the formation of a scar composed of myofibroblasts since adult CMs have little or 
no ability to regenerate. This scar tissue replacing the lost CMs supports the cardiac structure after 
injury. Over time, however, this dysfunctional fibrotic tissue leads to progressive deterioration of 
the heart function followed by heart failure and death, as the heart is unable to meet the workload 
demand (1). 
 
The treatment options to restore heart function in case of end-stage heart failure are heart 
transplantation or a ventricular assist device that can be attached to the weakened left ventricle of 
the heart to help increase blood flow to the body called the left ventricular assist device (LVAD) 
implantation.  These treatment options have huge limitations, e.g. the limited number of donor 
hearts available, heart transplant rejection, and with LVAD right ventricular failure due to setting 
of loading changes, physical functional limitations, more psychological distress and reduced 
quality of life (2-4).   
 
Current therapeutic means are therefore mostly palliative, relieving symptoms and prolonging life 
for a limited period (5). To date, the medical and surgical therapies are unable to address the main 
issue causing decreased function in the diseased or aging heart: loss of CMs (6). Moreover, the 
regeneration capacity of the heart although it seems to exist is insufficient in most patients with 
severe forms of heart disease (7, 8).  
 
Due to these major limitations, there is a significant clinical need for cardiac regenerative therapy. 
The main aim of cardiac regenerative therapies is to generate new contractile cells, to replace the 
damaged cells lost during injury and to restore normal structure and function of the heart. A 
considerable amount of research has been performed and is still underway to develop cardiac 
regenerative therapies. Somatic stem cells and progenitor cells from non-cardiac sources such as 




transplanted into the heart but are unable to remodel or heal the scar tissue, nor have they been 
able to activate differentiation of resident cardiac stem cells to support regeneration (9). 
 
Scientists in this era of regenerative medicine are focusing on actually curing heart problems, and 
not just treating them and delaying the vicious cycle leading to heart failure. Various approaches 
have been proposed thereafter such as induced pluripotent stem cell (iPSC) derived CMs.  
 
Regeneration of the myocardium can be potentially accomplished by focusing on one of the 
promising approaches like iPSC reprogramming followed by differentiation to desired cell types 
such as iPSC-CMs. 
 
 
5.2. INDUCED PLURIPOTENT STEM CELL DERIVED CARDIOMYOCYTES  
 
In 2006, ESC like cells named induced pluripotent stem cells (iPSCs) could be generated from 
fibroblasts using a cocktail of transcription factors, Oct4, Klf4, Sox2 and c-myc (OSKM) (10). 
This discovery of four transcription factors that made a huge cellular change was a major 
breakthrough. The rationale underlying the reprogramming strategy of Takahashi et al. was that 
ectopic expression of the transcription factors, which determine the pluripotent phenotype, would 
convert mature cells back into the pluripotent state (10). Starting out with 24 transcription factors, 
single factors successively being eliminated and resulting in a combination of OSKM to be 
sufficient to induce pluripotent reprogramming. iPSCs have come a long way ever since. Lately, 
iPSCs differentiation has also been induced by chemical means (11).  
 
iPSCs have been hailed as an ideal replacement for ESCs and have become an important tool 
providing an unlimited supply of once-inaccessible tissues for research. They can be differentiated 
into any desired cell type. Directed differentiation methods have been developed to obtain CMs 
efficiently from iPSCs (12-16). Additionally, an autologous cell therapy setting is possible with 
patient-specific iPSC derived CMs. However, CM maturity, tissue regeneration, heterogeneity, 





Nevertheless, iPSCs brought regenerative medicine closer to its aim. Reprogramming to 
pluripotent cells convincingly proved that end-stage differentiated cells can be reprogrammed and 
pushed back up to the top of Waddington’s epigenetic landscape.  
Besides reprogramming to iPSCs raised the possibility that somatic cells could transdifferentiate 
into desired cell types without passing through a stem cell stage in a process called direct 
reprogramming.   
 
 
5.3. DIRECT CARDIAC REPROGRAMMING  
 
About 30 years ago Davis et al. showed that overexpression of a single transcription factor MyoD, 
could convert fibroblasts to skeletal muscle in vitro (18) proving that the marbles could take 
different routes and dedifferentiate or transdifferentiate moving in different routes of the epigenetic 
landscape. Transcription factors (TFs) like MyoD were discovered for various cell types and direct 
lineage conversions have since been reported for some cell types. For example, CEBP TF can 
convert B Lymphocytes to macrophages; GATA-1 transformed myeloblasts to erythroid 
megakaryocytic cells, and; inner ear cells can be reprogrammed to hair cells by Math1 (19-22). 
  
Unfortunately, for CMs, no single “master regulator” has been, identified. Nevertheless, the 
discovery and ability to transdifferentiate has paved the path for new treatment approaches.  
 
Thus, lessons from iPSCs generation paved the way to direct reprogramming by forced expression 
of a cocktail of transcription factors. Direct cardiac reprogramming strategy involves 
reprogramming cells from the vast pool of non-myocytes, such as cardiac fibroblasts (CFs) in the 
heart. CFs in the healthy heart account for up to 10% of the total cell population, while endothelial 
cells are 44%, cardiomyocytes 30% and other non-myocytes 15% (23). Myocardial infarction 
leads to irreversible loss of CMs followed by a reparative response in which the damaged tissue is 
replaced with a fibrotic scar produced by CFs proliferation (24). Thus, acknowledging that CFs 
are activated and increased by replication in an injured heart tissue makes them an ideal candidate 
for cardiac reprogramming (25). Moreover, reprogramming from neighboring tissue or resident 
cell types has the advantage of being physically proximal to the injury site, will favor tissue 





Applying the concept of iPSC reprogramming, Ieda et al. tested fourteen different factors and 
identified a combination of three transcription factors Gata4, Mef2c and Tbx5 (GMT) sufficient 
for reprogramming mouse post-natal fibroblasts into a cardiomyocyte-like cell state (27).  
Varieties of approaches have ever since been designed to steer fibroblast cells directly into a 
cardiomyogenic fate, each employing a unique combination of cardiac-specific transcription 
factors, miRNAs and/or chemical molecules. Following the initial report by Ieda et al., other 
groups also reported the generation of cardiomyocyte-like cells from mouse fibroblasts based on 
the same factors or microRNAs plus additional factors (28-37).  
 
To advance cardiac reprogramming technology, the knowledge gained from studies using mouse 
system was translated into human cells. GMT alone was insufficient for cardiac induction in 
human fibroblast. However, in combination with Mesp and Myocd (GMTMM) or with Mesp and 
Esrrg (GMTEM), human CFs could be reprogrammed into CMs (38-40). Furthermore, following 
the proof-of-concept in vitro. Qian et al. and Mathison et al. showed that reprogramming of 
fibroblasts into CMs can be achieved in situ, by delivering reprogramming genes directly into the 
myocardium following myocardial infarction (MI) (41, 42). This strategy involves reprogramming 
cells from the vast pool of non-myocytes in the heart (25, 43-45). In vivo, cardiac reprogramming 
technology circumvents cell therapy associated challenges such as cell retention and homing. 
However, it brings with it a different set of challenges such as virus toxicity - immunogenicity 
towards virus or induced cell product, immaturity, cell heterogeneity, and low reprogramming 
efficiency.   
 
Mature functional iCMs do not proliferate as converted cells rapidly exited the cell cycle, making 
the regeneration of the heart even more challenging. Regardless of all the huge efforts such as 
modifications of stoichiometry, transcription factors, small molecules, micro-RNAs and 
epigenetic factors the reprogramming efficiency and maturity of the iCMs remain an important 
obstacle to overcome before clinical applications (28-36, 46-50).  
 
Therefore, to generate effective regenerative therapy, we need to reprogram cardiac fibroblasts 









Figure 2: Schematic of direct reprogramming of cardiac fibroblasts into cardiomyocyte like 





5.4. LENTIVIRAL SYSTEM  
 
Successful reprogramming of cells requires short-term overexpression of transcription factors and 
efficient vectors. The sufficient presence of these exogenous transcriptional factors activates the 
endogenous gene regulatory networks, thereby establishing stable reprogrammed target cell 
phenotypes. Numerous approaches for factor delivery have been used over the past decades 
including viral vs. non-viral as well as DNA-based and RNA-based. Viral delivery systems like 
MMLV replication-defective retrovirus (RV), HIV-based self-inactivating lentivirus (LeV), 
replication-defective non-integrating adenovirus (AV) and adeno-associated virus (AAV) have 
emerged as powerful tools for transgene delivery over the past decades (Table 1).  
 
AV can deliver genetic material up to a size of 30kb. However, AV provokes a strong immune 
response (51). To address this issue, AAV was developed, but with a decreased carrier size of 5kb. 
RV and LeV systems, on the other hand, can efficiently transfer up to 8kb genetic material into 
the cells, which will then be integrated into the cellular genome. Additionally, LeV and RV can 
be pseudotyped with a wide variety of envelope proteins to broaden tropism; they have the ability 
to produce polycistronic vehicles generating less heterogeneous cells. LeV infection has the 
advantage of high-efficiency infection of dividing and non-dividing cells over RV gene-therapy 
method.  
 
Other transduction systems are currently being evaluated for reprogramming efficacy by various 
groups. However, when we initiated this project, the emphasis on LeV appeared justified: (i) the 
tropism of these vectors is broad and known to include dividing and non-dividing fibroblasts, 
which can be efficiently transduced at a low MOI, (ii) the cell type specificity can be readily 
adapted via pseudotyping, and (iii) the relative ease of production.  
Therefore, in this study, LeV transfection system was used to target dividing and non-dividing 
cardiac fibroblasts and for the proof-of-concept. For further advancement, we need to switch to a 
transfection system with similar or better transfection efficiency as LeV and one that is safe for 














Genome ss-RNA (+) ss-RNA (+) dsDNA ssDNA 
Genome size 8-10kb 8kb 37.7kb 4.7kb 
Packaging capacity 2.5-5kb 2.5-5kb 3-8kb 2.5-4.5kb 
Virion size 80-130nm 80-130nm 90-100nm 20-25nm 











>90% 90% Low Low 
Replication No No No No 
Genome integration/  
Risk insert 
mutagenesis 























Yes Yes  
 





5.5. MOLECULAR BEACON TECHNOLOGY  
 
Reprogramming cell cultures contain CFs as well as transdifferentiated target cells. Direct 
application of these cells cultures in clinical studies could induce arrhythmias, thus sorting 
methods to obtain a pure population of the target cells are necessary. FACS based cell sorting or 
enrichment of cells relies on cell surface markers. However, the inability to target and sort 
MYH6/7 or cTnT specific CMs is a major drawback. Studies have shown that molecular beacons 
enable detection of live cells by targeting cell-type-specific mRNAs (52-54).   
Thereafter, a molecular beacon-based method for the isolation of cardiomyocytes (CMs) from a 
differentiating culture of iPSCs by targeting highly expressed specific mRNAs was developed. 
MBs targeting cardiac troponin T (cTnT) and myosin heavy chain beta (MYH6/7) mRNAs, which 
are highly expressed in CMs were specifically designed and validated (55-58). 
 
Molecular beacons are single-stranded oligonucleotide hybridization probes that form a stem-and-
loop structure. The loop contains a probe sequence that is complementary to a target sequence and 
the stem is formed by complementary arm sequences located on either side of the probe sequence. 
A fluorophore is linked to the 5’ end and a quencher is covalently linked to the 3’ end. MBs do 
not fluoresce in the absence of targets, when the stem places the fluorophore close to the quencher, 
eliminating the ability to fluoresce. When the probe encounters a target, the MB undergoes a 
structural change forming a probe-target hybrid that is longer and more stable than the stem hybrid 
enabling the fluorophore to fluorescence brightly. MBs can be designed to target human genes, 
mouse genes, or in some cases both. The MBs targeting the MYH6/7 mRNA described in this 
protocol was designed for both mouse and human genes.   
 
The assumption at the heart of this work was that the MB-based technology followed by FACS 
based sorting could be a highly specific and efficient method for purifying cells by directly 
targeting specific mRNA. The MB technology is an innovative and clinically compatible 











6. AIM  
 
iCMs can be generated from iPSC-CMs and direct cardiac reprogramming of fibroblasts. 
However, there are limitations concerning the iCMs reprogramming efficiency and maturity. We 
hypothesized that we could improve direct cardiac reprogramming. We thus developed a protocol 
for the genetic reprogramming of cardiac fibroblasts into iCM precursor cells (iCMPs) with CM 
lineage commitment. We believe these cells may bypass the problems related to mature iCMs and 
may represent as a better candidate for cardiac regenerative therapies. Therefore, the following 
aims were pursued in my project:  
 
Part 1:  To achieve baseline cardiac reprogramming – To obtain iCMs from CFs using 
transcription factor combinations that have already been successful in generating 
iCMs such as Gata4, Mef2c, Tbx5 (GMT) and Mef2c, Myocd, Tbx5 (MMT).  
 
Part 2:  Genetic manipulation of neonatal cardiac fibroblasts that are considered 
epigenetically more plastic into induced cardiomyocyte precursor cells (iCMPs) via 
lentiviral transduction with a cocktail of cardiomyogenesis-related transcription 
factors Gata4, Mef2c, Tbx5, and Myocd.  
 
Part 3:  Enrichment, characterization and global transcriptome analysis of iCMPs.  
 
Part 4:  In vivo translation: Evaluation of the regenerative and therapeutic potential of 








7.1. Lentivirus  
Gene/ Inserts Source 
eGFP IRES-eGFP, VSV-G pseudotyped 




IRES-GFP, VSV-G pseudotyped, NEO antibiotic 
resistance 
Mef2c 
IRES-GFP, VSV-G pseudotyped, NEO antibiotic 
resistance 
Tbx5 
IRES-GFP, VSV-G pseudotyped, ZEO antibiotic 
resistance 
Myocd 
IRES-GFP, VSV-G pseudotyped, ZEO antibiotic 
resistance 
 
7.2. Bacteria   
Bacterial strain Source 
Escherichia coli K12 derivatives Gift from Dr. Manfred Gossen’s lab 
 
7.3. Cells  
Product Source Identifier 
Mouse neonatal cardiac 
fibroblasts, C57BL/6 
PeloBiotech PB-C57-6049 
HT1080 Gift from Dr. Manfred Gossen’s lab 
Hek293  Gift from Dr. Manfred Gossen’s lab 
𝛼MHC-mCherry CMs Derived from transgenic 𝛼y-mCherry mice  





7.4. Molecular beacons  
Product Sequence 5'-3' Fluorophore Source 
DELC  
(Delivery control) 
ACG ACG CGA CAA GCG 
CAC CGA TAC GTC GT 
Cy5 
Sequence from 







ACG ACG CGA CAA GCG 




CCT CCA TCT TCT TCT 
TCA CGG AGG 
 
 
7.5. Laboratory equipment’s   
Product Source 
Centrifuge Eppendorf 
CO2 incubator Binder 
Clean bench / Flow hood Ulf Lippmann Labortechnik 
Research Plus Pipettes Eppendorf/ VWR 
Water bath Thermo Scientific 











7.6. Animal cell and bacterial culture reagents, chemicals and enzymes 
Product Source  Identifier  
DMEM high glucose: 4.5 g/l  Life Technologies 
31966 
DMEM low glucose: 1 g/l Life Technologies 21885 
FBS (pre-tested lots) Life Technologies 10270106 
Packaging plasmid 
Gift from Dr. Manfred Gossen’s lab 
Envelope plasmid 
LB-Agar for molecular biology Roth X965.1 
LB-Medium for molecular biology  Roth X964.1 
Ampicillin  Roth K029.1 
Gelatin Pan P06-25200 
Matrigel Corning 354230 
Medium 199  Life Technologies 41150-020 
PBS  Life Technologies 14040166 
Trypan blue dye  Sigma-Aldrich Chemie GmbH T8154-20 
TrypLE Express  Life Technologies 12605010 
Penicillin/Streptomycin  Lonza, Basel DE17-602E 
G418 Sulfate Fisher Scientific BP673-5 
Hexadimethrine bromide 
(Polybrene)  
Sigma-Aldrich Chemie Gmbh 
107689 
FGF-basic PeproTech GmbH 100-18B-10 
FGF-10 PeproTech GmbH 100-26-25 




BMP-4 R&D Systems 314-BP-010 
VEGF PeproTech GmbH 100-20-10 
RPMI 1640  Life Technologies 61870010 
IMDM Gibco 12440053 
F12 medium Gibco  
N2 supplement Thermo Fisher 17502048 
B27 supplement Thermo Fisher 17504044 
B27 supplement without Vitamin A Thermo Fisher 12587010 
GlutaMAX 100X supplement  Gibco 35050061 
Bovine serum albumin (BSA) Roth CP77.1 
β-mercaptoethanol Carl Roth 4227.3 
1-thioglycerol (MTG) Sigma-Aldrich Chemie GmbH M6145 
4% Formaldehyde Thermo Scientific Pierce 28908 
TritonX-100 Roth 3051.3 
Goat serum Life Technologies GmbH 16210064 
IWR-1 Selleckchem SEL-S7086 
IWP2 STEMCELL Technologies 72124 
5-Azacytidine Abcam AB120842 
X-treme GENE HP DNA 
Transfection Reagent 
Sigma-Aldrich Chemie GmbH 
(previously Roche Diagnostics) 
06365752001 
PEI (Polyethylenimine)  Polysciences 24765-2 








Hoechst 33342, trihydrochlorid Invitrogen H3570 
2,3-Butanedione monoxime (BDM) Sigma-Aldrich Chemie GmbH 
B0753-25 
Leibovitz's L-15 Medium Life Technologies 11415064 
Collagenase B Roche  11088815001 
 
 
7.7. Antibodies  
 
7.7.1. Primary Antibodies 
Target Species    Source   Identifier  












Thermo Fisher Scientific  MS-295-P0 





































Santa Cruz Biotechnology, 
Inc. 
sc-6251 
PDGFR-a Antibody (C-9) 
Mouse 
monoclonal 







Mef2c (D80C1) XP  
Rabbit 
monoclonal 















7.7.2. Secondary Antibodies 
Product Source   Identifier  
Donkey Anti-Chicken, FITC  Invitrogen SA1-72000 
Alexa Fluor 647 Goat Anti-Mouse NEBiolabs 4410S 
Alexa Fluor 488 Goat Anti-Mouse Invitrogen A10684 











T25, T75 and T175 cell culture flasks Greiner Bio-One GmbH/ VWR 
6, 12, 24 and 48 well cell culture dishes CELLSTAR 
15 and 50ml Falcon tubes Greiner Bio-One GmbH/ VWR 
Hemocytometer  Roth 
MicroAmp Optical 96-Well Reaction Plate Life Technologies 
MicroAmp Optical 384-Well Reaction Plate with 
Barcode 
Life Technologies 
Stericup-HV, 0,45 µm, PVDF, gamma-sterilisiert 
EMD Millipore/ Merck Chemicals 
GmbH 
Cell strainer  VWR 
Tube, OptiSeal™, Polypropylene, 32.4 mL, 26 x 77 
mm  
ROTORS: Beckman Coulter SW32 Ti 
Beckman Coulter 
Spacer, Ultem, Tube, 25 mm  
ROTORS: Beckman Coulter SW32 Ti 
Beckman Coulter 
FACS tube with filter cap Corning/ Falcon  
5, 10, 25 and 50ml Serological pipets Roth  









7.9. Instruments  
Product Source 
MACSQuant Erato analyzer BCRT, Flow Cytometry Lab  
 Miltenyi Biotech GmbH Ariall Calliope Cell Sorter 
Operetta high content screener  PerkinElmer, Rodgau, Germany 
Zeiss Axio Observer fluorescence microscope 
Carl Zeiss Microscopy GmbH, Jena, 
Germany 
Odyssey Infrared Imaging System LI-COR Biosciences 
NanoPhotometer Implen 
2100 Bioanalyzer system Agilent 
Illumina HiSeq 1500 system Illumina 
Eppendorf Mastercycler ep gradient S 
realplex2 
Eppendorf AG 














7.10.  Kits  
Product Source Identifier 
Nucleobond Xtra Midi EF  
(Plasmid amplification) 
Macherey-Nagel GmbH & Co. K 
740420.50 
BCA Protein Assay Kit Pierce/Thermo Scientific 23227 
RNeasy mini kit Qiagen  74106 
SuperScript III First-Strand 
Synthesis System 
Life Technologies, Carlsbad, 
California, USA 
18080-051 
Power SYBR Green PCR 
Master Mix 
Life Technologies, Carlsbad, 
California, USA 
4368706 
RNA 6000 Nano Kit Agilent M.Sc. Ulrike 
Krüger  






Magnetic Isolation Module 
NEB 
DNA 1000 Kit Agilent 
NEBNext Ultra RNA Library 
Prep Kit for Illumina 
NEB 
Qubit dsDNA BR Assay Kit 
and Qubit 3.0  
ThermoFisher 
PKH26 Red Fluorescent Cell 
Linker Mini Kit for General 
Cell Membrane Labeling 
Phanos Technologies/ Sigma-










7.11. Software for data analysis 
Product Source 
FlowJo BD 
AxioVision Carl Zeiss Microscopy GmbH, Germany 
Operetta Harmony (operetta) 
Columbus (server) 
PerkinElmer, Rodgau, Germany 




7.12. Animal experiment  
Product Source 
C57BL/6 mice  Charles River Laboratories 
Glucose G-5% B Braun Melsungen 
Isoflurane AbbVie Inc. 
Ventilator System  
Connecting kit for anesthesia system to Minivent 
Hugo Sachs Elektronik-
Harvard Apparatus GmbH 
Abbocath-T, 20G x 30mm intubation Catheter Intermed Service GmbH 
Prolene blau 7-0 75cm 2XBV175-8 EH7405H  
(suture thread 9.3mm 3/8c 75cm) 
Ethicon Sutures 
Ethicon Vicryl 4-0 Plus Viol GEFL  
(suture thread 19mm 3/8c 70cm) 
Ethicon Sutures 
Syringe Omnifix-F Solo without cannula, 1 ml 
(cell injection syringe) 
Intermed Service GmbH 
BD Micro-fine syringe 0.3ml  BD Medicals 





7.13. Primers for real-time PCR  
















































8.1. Cell culture 
 
Cardiac fibroblasts (CFs): Cryopreserved neonatal CFs were purchased from PELOBiotech 
GmbH. The cells were plated at density of 5,000 cells/cm2. The cells were maintained in basic 
culture medium, DMEM supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS) 
and 100U/ml penicillin, 100μg/ml streptomycin (Pen/Strep) in T75 cell culture flasks coated with 
0.2% gelatin and incubated at 37°C and 5% CO2 in a humified incubator. All experiments were 
performed with CFs between passages 2-5.  
 
HT1080 and Hek293 cells were maintained in basic culture medium, DMEM supplemented with 
10% fetal bovine serum (FBS) and Pen/Strep in T75 cell culture flasks and incubated at 37°C and 
5% CO2 in a humified incubator.  
 
Neonatal α-MHC-mCherry cardiomyocytes were isolated from day 2-5 old mice following a 2 
day Jove protocol (59). The hearts were carefully extracted, washed in PBS (- -) supplemented 
with 20mM 2,3-Butanedione monoxime (BDM). The hearts were then minced thoroughly using a 
curved scissors and incubated overnight in isolation medium (20mM BDM in L-15 medium) with 
gentle agitation. The following day tissue digestion was done using a digestion mix (20mM BDM, 
1.5 mg/ml collagenase B, 0.125% trypsin in L-15 medium) and the supernatant was filtered 
through a cell strainer. Red blood cells were removed using the red blood cell lysis solution and 
the Percoll gradient method was used for CMs purification. The cells were then count and plated 
at a density of 100,000 cells/cm2. 
 
 
8.2. Plasmid DNA 
 
p6NST50 lentiviral (LeV) vectors containing the coding regions of Gata4, Mef2c, Tbx5, MyocD 
and eGFP were a gift from Stephanie Protze. The transcription factors were cloned into the 
multiple cloning site of the p6NST50-Zeo (Tbx5, MyocD), p6NST-52-Neo (Gata4, Mef2c) 
lentiviral vectors, containing a spleen focus forming virus (SFFV) U3 promoter and an internal 




neomycin or hygromycin resistance protein to facilitate selection of infected cells. As control the 
p6NST50-Zeo lentiviral vector only expressing EGFP-Zeo was used (30). Stephanie Protze did 
the cloning. 
 
Lentiviral vectors were eluted from filter paper with double distilled water (ddH2o). LB agar (15g 
LB agar in 1-liter water) plates were prepared. LB agar plates were streaked with LeV vectors and 
were used to isolate individual colonies. The bacteria were then cultured in LB medium (20g LB 
broth powder in 1liter water) containing ampicillin at 37°C as overnight cultures to grow up 
sufficient numbers of bacteria necessary to isolate enough plasmid DNA. Plasmid DNA was 
isolated using Machery Nagel Plasmid amplication kits following the manufacturer’s 
recommendations. The plasmids were then sent to SEQlab for verification.  
For functional verification, the plasmids were transfected onto Hek293 cells. Two days after 
transfection, the cells were stained for Gata4, Mef2c, Tbx5 and Myocd respectively to look for the 














8.3. Lentivirus Work  
8.3.1. Lentivirus Production  
 
The virus production protocol used was based on the second-generation lentiviral vector system. 
2nd generation packaging systems: express the HIV gag, pol, rev, and tat genes all from a single 
packaging plasmid such as psPAX2, whereas a 3rd generation packaging systems do not express 
tat, it does not express any viral genes. They are considered safer than 2nd generation systems but 
maybe more difficult to use because they require transfection with four separate plasmids to create 
functional lentiviral particles. However, they can be considered for future clinical translation.  
Once the plasmid sequence was verified and plasmid function was validated, Hek293 cells were 
plated at density of 83,333 cells/cm2. The following day the cells were transfected using the PEI 
transfection method with one of the transgene-containing plasmid, the packaging plasmid psPAX2 
and the VSV-G envelope expressing plasmid pMD2.G. Medium (DMEM supplemented with 10% 
HI-FBS and Pen/Strep) was replaced with fresh media 5-6 hours after transfection.  
Virus-containing supernatant was harvested 24 hours after transfection replaced with fresh 
medium and harvested again 12 hours after medium change. The harvests were filtered with 
0.45µm PVDF stericups to remove any cell debris and concentrated up to 100-fold by 
ultracentrifugation for 2 hours at 22,000 RCF. The viral pellets were resuspended overnight at 4°C 
in PBS under shaking. Aliquots were prepared and stored at -80°C.  
 
 
8.3.2. Lentiviral titration 
 
The titers of the produced LeV were determined by infecting HT1080s and CFs. The cells were 
plated at a density of 5,000 cells/cm2. After 24 hours, the cells were transduced with dilutions of 
the concentrated virus (0.5, 1, 2.5, 5 and 10µl/well). Medium was replaced after 18-20 hours and 
cells were incubated for 2-3 days. The percentage of infected cells (GFP+ cells) was determined 
by flow cytometry. Cells were thoroughly trypsinized to obtain single cell suspensions and 
centrifuged at 300 RCF for 5 minutes. The pellets were resuspended in FACS buffer (2% BSA 
and 2 mM in PBS - -) and filtered through a 35μm mesh to remove cell aggregates. Cells were 
analyzed using the MACSQuant Erato analyzer. Only samples with a concentration between 2 and 






The titers were calculated using the following equation: 





𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑛 𝑡𝑟𝑎𝑛𝑠𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑑𝑎𝑦 ∗ (
% 𝑜𝑓 𝐺𝐹𝑃 + 𝑐𝑒𝑙𝑙𝑠
100 )




8.3.3. Lentivirus validation  
 
The competency of each of these transcription factors - Gata4, Mef2c, Tbx5 or Myocd was 
confirmed by correct transgene expression upon lentiviral infection. Hek293 and HT1080 cells 
were plated at a density of 5,000 cells/cm2. The following day the cells were infected with the 
LeVs and the medium was replaced after 12 hours. Three days after infection, the cells were 




8.4. Cardiac Reprogramming  
 
CFs were seeded onto gelatin-precoated T75 cell culture flasks at a density of 5,000 cells/cm2. 
Twenty-four hours later cells were infected with the lentiviral GMTMy cocktail at a multiplicity 
of infection (MOI) of 10. Basic culture medium, DMEM supplemented with 10% fetal bovine 
serum (FBS) and Pen/Strep was replaced with cardiac reprogramming medium (CRM) composed 
of DMEM-LG and M199 (3:1) and supplemented with 10% FBS and Pen/Strep. To enhance 
lentiviral transduction CRM was supplemented with 8μg/ml Polybrene during LeV addition. As 
control, CFs were infected with LeV eGFP at a MOI of 10 and treated similarly.  
Three days after lentiviral infection the cells were trypsinized, counted and re-plated at a density 
of 5,000 cells/cm2 onto gelatin-precoated dishes. G418 was added for antibiotic selection at a 
concentration of 0.5mg/ml as determined by pretests on CFs. CRM was changed every 2 days and 





8.5. Immunofluorescence  
 
8.5.1. Immunofluorescence staining of adherent cells  
 
At indicated time points, cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) 
for 20 minutes, permeabilized using 0.25% TritonX-100 in PBS (PBST) for 15 minutes and 
incubated in blocking buffer (PBST + 10% serum) for 30 minutes at room temperature (RT). 
Thereafter, primary antibodies (Antibody Table 8.5.1) were diluted in blocking buffer and added 
to the cells for overnight incubation at 4ºC. The following day, secondary antibodies (Secondary 
Antibody Table 8.5.2) were also diluted in blocking buffer and added to the cells after three PBS 
washes for, a 2 hour incubation in the dark at RT. Nuclei were counterstained with DAPI for 5 
minutes at RT and the cells were finally washed again three times with PBS. Images were acquired 
using the Operetta high content screener system and the Zeiss Axio Observer fluorescence 
microscope. The high content screener was used for quantification of the stained cells, while the 
Axio Observer was used for high-resolution images of protein expression patterns.   
 
 
8.5.2. Immunofluorescence staining of harvested cells/ FACS 
 
At indicated time points, cells were thoroughly trypsinized to obtain single cell suspensions and 
centrifuged at 500g for 5 minutes. Cells were washed with PBS, incubated in 4%PFA fixation 
buffer for 20min. Primary antibody solutions were added to the cells and incubated for 20 minutes 
at RT. The cells were then washed with PBS and incubated in the secondary antibody solution for 
30 minutes at RT. Both primary and secondary antibody solutions were prepared in staining buffer 
PBST-S (PBS and 0.25% TritonX-100 and 10% BSA). The pellets were then washed 3 times with 
PBS, centrifuged and resuspended in FACS buffer (2% BSA, 2mM EDTA in PBS--) and filtered 
through a 35μm mesh to remove cell aggregates. During analysis, cells were counterstained with 
DAPI to label dead cells. The cells were measured using the MACSQuant Erato analyzer and data 
were analyzed with FlowJo10 software.  
Gating strategy: Forward and side scatter gating was done to obtain the population of interest. A 
pulse geometry gating was done to get rid of cell clumps if any. Following a subgating using a 





8.6. Molecular beacon work  
 
8.6.1. Molecular beacon transfection  
 
MBs that target unique sites in MYH6/7 mRNA in both mouse and human (55) were used. 
MicroSynth synthesized these MBs, with a Cy5 fluorophore at the 5′ end and a Black Hole 
Quencher 2 at the 3′ end (Materials table 8.3.). The cells were transfected with Cy5-conjugated 
DELC (delivery control), NEGC (negative control) and MYH6/7 (myosin heavy chain 6/7) MBs 
using the XtremeGENETM HP DNA Transfection Reagent. The DELC MB is modified to have 
two identical fluorophores instead of a dye-quencher pair and is used as a delivery control probe 
for delivery studies and the NEGC does not match with any mRNA sequence in the genome of 
interest, thus any signal from this would be non-specific background signal (57).  
For initial concentration tests, the cells were transfected with either - 0.5μM MB or 1μM MB to 
determine the optimal MB concentration needed for efficient transfection. Additionally, the cells 
were transfected with a reaction mix of MB and transfection reagent at a ratio of 1:1, 1:2, 1:3 and 
1:4 to determine the optimal ratio for our target cell type CFs. The cells were incubated in a 
humidified, 5% CO2 atmosphere at 37°C for 2-24 hours.  The cells were then rinsed thoroughly 
with PBS and stained with Hoechst 33342 a nuclear dye for 15 minutes. These cells were washed 
thoroughly again with PBS. Operetta high content screener was used to capture 20X-images that 
covered the center of the culture surface. Harmony® software was used for quantitative image 
analysis to determine the Hoechst+ cells for the total cell number and the Cy5+ cells to determine 
the percentage of MB+ cells.  
 
8.6.2. Molecular beacon-based sorting 
 
Two weeks after LeV infection, target cells were transfected with Cy5-conjugated molecular 
beacons MYH6/7 using the XtremeGENETM HP DNA Transfection Reagent. The cells were 
transfected with a reaction mix containing- 1μM MB and Transfection Reagent at a ratio of 1:4, 
which was the optimal ratio for our target cell type, determined by initially, conducted protocol 
establishment experiments. The cells were incubated in a humidified, 5% CO2 atmosphere at 37°C 
for 4 hours. Thereafter, the cells were washed thoroughly with PBS, harvested by trypsinization 
and resuspended in sorting buffer (2% BSA and 2mM EDTA in PBS --). iCMPs were sorted using 




























8.7. RNA Sequencing 
 
RNA sequencing was performed by, M.Sc. Ulrike Krüger of the BIH core facility Genomics at 
Charité – Universitätsmedizin Berlin. 
RNA samples were quantified with a NanoPhotometer and the quality of totalRNA isolates was 
accessed by the RNA 6000 Nano Kit on 2100 Bioanalyzer system. Poly-(A)-selection was 
performed from 500ng total RNA utilizing the NEBNext Poly(A)mRNA Magnetic Isolation 
Module according to the manufacturer’s instructions with subsequent library preparation using the 
NEBNext Ultra RNA Library Prep Kit for the Illumina system. Success of library preparations 
was confirmed by analyzing the fragment size distribution utilizing the DNA 1000 Kit on a 2100 
Bioanalyzer and library concentration was quantified by Qubit® dsDNA BR Assay Kit and Qubit 
3.0. After equimolar pooling all samples were sequenced on an Illumina HiSeq 1500 system with 
Rapid Mode chemistry v2 (50 cycles, single-read). 
 
 
8.8. Quantitative real-time PCR 
 
Total RNA was isolated from enriched iCMPs 2 weeks after LeV infection and after MB-based 
sorting, CFs and adult heart tissue, using the Qiagen RNeasy mini kit.  Subsequently, 100ng of 
each RNA sample were random hexamer primed and reverse transcribed into cDNA using the 
Invitrogen SuperScript III First-Strand Synthesis System. Quantitative real-Time PCR was 
performed using the Applied Biosystems Power SYBR Green PCR Master Mix and an Applied 
Biosystems MicroAmp Optical 384 Well Reaction Plate. Each PCR reaction was performed in 
triplicates. The following PCR program applied in Quant Studio: initial denaturation: 95°C 10 
minutes; 50 cycles: 95°C 15 seconds, 60°C 30 seconds, 72°C 30 seconds; final step: melting curve 
program. PCR primers were purchased from Eurofins Genomics. The following algorithm 
quantified relative gene expression levels of the markers in iCMPs, parental CFs and heart tissue 







8.9. iCMPs proliferation    
 
Enriched iCMPs were seeded onto gelatin-precoated culture dishes at a density of 5,000 cells/cm2 
and maintained in CRM. The cells were regularly passaged every 3 days and cell counts were 
performed using a hemocytometer, viability was determined by staining with Trypan blue dye. 
The total cell numbers per split determined the cell fold increase. 
 
8.10. iCMPs maintenance 
 
Various cardiomyocyte specification factors were screened for maintenance of iCMP phenotype. 
Considering the sequencing results and heart development knowledge, iCMPs were, maintained 
in culture medium supplemented with factors/factor cocktails - Ascorbic acid, BMP4, FGF2, 
FGF10 and VEGF. The cells were then monitored regularly for morphological changes and 
MYH6/7 expression.  
 
8.11. iCMPs differentiation 
 
For the generation of mature CMs from iCMPs, the effectiveness of previously established 
differentiation conditions were tested (60-62) 
(1) In the first condition, the iCMPs were seeded onto Matrigel coated dishes and cultured in 
SFDM (IMDM:F12) (3:1) supplemented with 0.5x N2, 0.5x B27 without Vitamin A, 1x 
GlutaMAX, 0.05% BSA, 450μM 1-thioglycerol (MTG), and 250μM ascorbic acid), and 
supplemented additionally with 5μM IWP2.  
 
 (2) In the second condition, iCMPs were seeded onto 0.2% gelatin coated dishes and cultured in 
cardiac differentiation medium (CDM) composed of RMPI 1640 supplemented with 0.5x N2, 1x 
B27, 0.5% GlutaMAX, 0.05% BSA, and 0.1mM β-mercaptoethanol. For the first six days of 
culture in CDM, the medium was supplemented with 5μM IWR-1.  
 
(3) In the third condition, these cells were cultured on cardiac extra cellular matrix (cECM) to 




media and supplement will aid the maturation process. The cells were monitored regularly for 
morphological changes, spontaneous contractions, and cardiac marker expression.  
(4) Additionally, iCMPs were cultured on 0.2% gelatin coated dishes and maintained in 




8.11.1. Co culture 
 
Additional mechanical, electrical and paracrine stimulation was provided to proliferative iCMPs 
by culturing them with either iPSC-derived CMs or mouse neonatal α-MHC-mCherry CMs on 1% 
gelatin coated dishes. The iPSC-CMs were labeled with the cell labeling dye red in order to 
distinguish them from the iCMPs. The cells were plated at a ratio of 1:4 and 1:10 iCMPs to CMs 
and maintained in differentiation medium mentioned above. The co culture was monitored 
regularly for 10days, for morphological changes, differentiation and spontaneous contraction of 
the iCMPs stimulated by the CMs.  
 
 
8.12. Animal experiments  
 
8.12.1. Cell preparations for in vivo experiments  
 
To obtain sufficient number of iCMPs, CFs were plated onto T175 dishes for large-scale cultures. 
They were reprogrammed with LeV cocktail GMTMy as mentioned in Cardiac Reprogramming. 
Two weeks after LeV infection the cells were sorted based on MB selection for MYH6/7 as 
previously mentioned in Molecular beacon work.  
The sorted cells were cultured and expanded in CRM to produce cell doses of 500,000 cells/mouse. 
To obtain control eGFP-CFs, CFs were plated onto T175 dishes and infected with LeV eGFP, and 
cultured similarly to the iCMPs in CRM but without antibiotic selection. The CFs were sorted 
based on their eGFP signal. The sorted cells were cultured and expanded to produce cells doses of 
500,000 cells/mouse. All cells of passage 3 and 4 were used for cell injections, with cells after sort 




8.12.2. Animal care  
 
In this experiment, C57BL/6 male mice of age 8-9 weeks were purchased. The mice were housed 
in the Forschungeinrichtung für Experimentelle Medizin (FEM) of Charité – Universitätsmedizin 
Berlin. Two days before the start of experiments the mice were shifted into a new cage with nesting 
material and drinking water was replaced with 5% glucose. After surgery the mice cages were kept 
on a heating pad for warmth and recovery. The mice were monitored daily and weighed weekly.  
 
8.12.3. Induction of myocardial infarction in mice and treatment  
 
The project protocol including surgery and all examinations G0288/16 (Table 2) was approved by 
the Landesamt für Gesundheit und Soziales Berlin (LaGeSo) (State Office of Health and Social 
Affairs Berlin). Ten to twelve-week-old wild type male C57BL/6J mice were used.  
 
For induction of myocardial infarction (MI), mice were anesthetized 30 minutes before surgery. 
Sedation depth was considered adequate when there was no response to tactile stimuli and hind 
limb pedal withdrawal reflex provoked with pinching. The mice were fixed in a supine position, 
given glucose injection and intubated with an Abbocath-T, 20G x 30mm intubation catheter. The 
general ventilator settings were 180 strokes/minute, volume 250µl/stroke and Oxygen 2%. 
Following a left anterolateral thoracotomy and removal of the pericardium, the left anterior 
descending artery was ligated using a suture thread 7-0 prolene BV175-8 9.3mm. Myocardial 
ischemia distal to the ligation was evident by the discoloration of the myocardium. Half million 
iCMPs, eGFP-CFs or PBS only (w/o Ca2+ and Mg2+) was injected at 2 points in the peri-infarct 
area (5μl each). The chest was closed and mice were given Carprofen subcutaneously after the 
operation for pain and the animals were allowed to recover. Sham operations with thoracotomy 


















Group Description  Measurement 
Number of 
animal’s incl. 






No myocardial infarction 
No therapy 
Histology: 
After 2 and 6 weeks 
  
Heart function measurement 
(Serial echocardiography:  
after 2, 4, and 6 weeks; 
Sacrifice and heart 






No therapy - PBS injection 
N=8 
N=16 






















8.12.4. Echocardiography  
 
Echocardiography was performed in mice 2, 4 and 6 weeks after MI and treatment, under light 
anesthesia with 2-3% isoflurane using the Vevo2100 echocardiography system equipped with a 
MS550D 22-55 hertz probe. EKV, B-Mode and M-Mode clips were acquired in the parasternal 
long axis and short axis view of the murine heart. Using the Vevo LAB analysis software left 
ventricular ejection fraction (LVEF), cardiac output (CO), stroke volume (SV) and volume diastole 
and volume systole were calculated from EKV based LV tracing. The left ventricular end-diastolic 
wall thickness and left ventricular fractional shortening (LVFS) were measured from the M-mode 




8.12.5. Histology and immunohistochemistry 
 
Six weeks after MI and treatment, experiments were terminated and mice were sacrificed by 
cardiac puncture, hearts were excised, dehydrated overnight in 15% sucrose solution and frozen 
in OCT embedding medium the following day. Cryo sections of 7μm were cut from apex to base 
and mounted onto super frost glass slides for histological analysis. Cryopreserved sections were 
fixed with 4% PFA and stained with Masson’s trichrome and H&E stain according to the 
















Figure 7: Echocardiography analysis of mice heart. (A) Left ventricular tracing of the long axis of 
the heart in an EKV clip for calculations such as the left ventricular ejection fraction, cardiac 
output and stroke volume. (B) Left ventricular tracing of the short axis of the heart in an M-mode 





8.13. Statistics  
 
Statistical analysis was performed using Graph Pad. Data are presented as mean ± standard error 
of the mean, unless otherwise indicated.  
 
8.13.1. Animal experiment data analysis  
 
Before the start of animal experiments, Sample size calculations was done. 
On the basis of our previous experiments average infarct size after 4 weeks in the control group = 
38%, in the treatment group = 28%, standard deviation = 5%, significance level α = 0.05, power 
= 0.8, analysis of variance with pairwise comparisons and α-adjustment for multiple comparisons 
(5 out of 6 possible comparisons). This results in a group size of N = 6.  
Based on the expected mortality (according to experience in previous attempts ~ 30%) the resulting 
total group size was N = 8 for the 2 week histology group. 
 
On the basis of our previous experiments average FS after 4 weeks in treatment group 1 = 22%, in 
treatment group 2 = 29%, standard deviation = 5%, significance level α = 0.05, power = 0.8, 
analysis of variance with pairs compare and α-adjust for multiple comparisons (5 out of 6 possible 
comparisons). The result is a group size of N = 12.  
Based on the expected mortality (according to experience in previous attempts ~ 30%) the resulting 
total sample size was N=16 for the 6 week time point. 
 
After animal experiments, for the echocardiographs data, an intergroup difference comparing each 
group to sham was done by one-way analysis of variance (ANOVA) followed by Bonferroni 
posttest. A value of p < 0.05 was considered statistically significant. P value summery *** <0.0001 
 
 
8.13.2. RNA Sequencing data analysis  
 
RNA sequencing data was analyzed by Dr. rer. nat. Karsten Jürchott, Bioinformatician of 
Development & Exploratory Lab (DEL), Charité – Universitätsmedizin Berlin. 
Fastq-files were quality controlled using fastqc (version 0.11.7 - Bioinformatics Group at the 




AdapterRemovel (63). Reads were aligned to the mm10 (GRCm38.82) version of the mouse 
genome using tophat (64) and bowtie2 (65). Counts per gene were calculated as the sum of all 
mapped reads within a gene region.  
Raw counts of protein-coding genes were normalized and variance stabilizing transformed using 
the DESeq2 package (66). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.). Variances across 
all samples were determined for each gene and 1000 genes with the highest variances were selected 
for unbiased analysis.  
Principle component analysis was either done with the plotPCA() function implemented in the 
DESeq2 package or with the in-built prcomp() function. The first two principle components were 
shown in the plots. Heat maps were generated after hierarchical clustering of the scaled data using 
euclidean distances. 
Differential expressed genes between treatment groups were defined by fitting negative binomial 
distribution models to the data. Raw p-values were adjusted for multiple testing by fdr/Bonferoni. 
An adjusted p-value below 0.05 (and a minimal absolute log2 fold change of 1) was used for 
selecting significant results. 
K-means clustering of differential expressed genes were performed using the in-built kmeans() 
function in R with 100 randomly defined start sets of 6 clusters in order to a robust reproducible 
result.  
Overrepresentation analysis of selected genes in terms of the gene ontology system was done using 
the topGO package (Adrian Alexa and Jorg Rahnenfuhrer (2016). topGO: Enrichment Analysis 
for Gene Ontology. R package version 2.32.0.), in R utilizing classical Fisher tests based on 
hypergeometric distributions. Due to the high redundancy of the gene ontology system, raw p-
values were not adjusted for multiple testing. Overrepresentation analysis of selected genes in gene 
sets of the Molecular Signature Database (67) was done by applying classical Fisher Tests based 
on hypergeometric distributions. Due to the high redundancy of some gene set collections with the 









9.1. Lentiviral system  
 
For successful transgene delivery, cellular reprogramming requires overexpression of specific 
transcription factors and efficient vectors. The initial part of this project was to primarily establish 
and standardize lentiviral production, concentration, titration, and validation.  
Prior to LeV production, plasmid DNA was verified for the correct sequence. Plasmid function 
was validated was by transfecting Hek293 cells with each of the TF plasmid Gata4, Mef2c, Tbx5, 
and Myocd. Three days after transfection when stained the cells showed nuclear localization of 
each of the TFs (Figure 8). 
 
High titer lentiviral vectors were then produced for all TFs Gata4, Mef2c, Tbx5, and Myocd (G, 
M, T, and My) using the 2nd generation lentiviral packaging system.  
Nuclear transgene expression was validated by immunofluorescence in Hek293 and HT1080 cells 
(Figure 9 and 10) and the transgene size was confirmed by western blots (data not shown).  
Following verification and validation, LeV for each of the TFs was produced in large scale and 
concentrated using ultracentrifugation. The competency of each of the IRES-eGFP lentiviral 
vectors was confirmed by infecting HT1080 cells, which resulted in eGFP-positive cells indicating 
successful transduction of the cells after LeV transduction. The titers of each of these LeV vectors 
ranged from about 50*10^6 to 300*10^6 TU/ml (Table 3). Titration was also done in CFs, wherein 
the resulting titers were much lower (data not shown). To determine the amount of virus needed 
for efficient transduction of CFs, CFs were infected with the LeV at a MOI of 1 to 5 based on the 
LeV titers obtained from the HT1080 cells. It was seen that at a MOI of 5 a maximum transfection 
efficiency of 60-90% and a plateau state was achieved as determined by flow cytometry (Figure 
11). Further on during the project, when LeV production and titrations were repeated, the MOI 
tests were done using only eGFP LeV. It was seen that the transfection efficiency was consistent, 




Figure 8: Validation of the lentiviral vectors: Immunofluorescence staining of Hek293 cells 
showing expression of Gata4, Mef2c, Tbx5 and Myocd (red), DAPI (blue) to label the cell 
nuclei and the eGFP vectors (green) after PEI-based plasmid transfection with the respective 






Figure 9: Proof of transgene expression: Immunofluorescence staining of Hek293 cells showing 
expression of Gata4, Mef2c, Tbx5 and Myocd (red), DAPI (blue) to label the cell nuclei and the 




Figure 10: Immunofluorescence staining of HT1080 cells showing expression of Gata4, Mef2c, 
Tbx5 and Myocd (red), DAPI (blue) to label the cell nuclei and the eGFP vectors (green) after 


























Lentivirus titer range (10^6 TU/ml) 
Cell Type HT1080 
Gata4 58 – 150  
Mef2c 55 – 68  
Tbx5 104 – 337  
Myocd 47 – 79  











Figure 11: Graphical representation of the transduction efficiency of each of the lentiviral vectors 
at MOI 1 to 5 in cardiac fibroblasts. The maximum transduction efficiency of 60-90% was 





9.2. Baseline cardiac reprogramming  
 
To achieve baseline cardiac reprogramming of CFs into iCMs as achieved by various other groups 
like Ieda et al. and Protze et al. (27, 30), we infected CFs with the LeV cocktails GMT and MMT. 
The cells were positive for GFP indicating successful transduction after infection with both GMT 
and MMT (data not shown). However, cell viability decreased markedly compared to the non-
infected fibroblasts before the onset of reprogramming and relevant cardiomyocyte gene 
expression. The striking results achieved by various other groups could not be reproduced in our 
initial attempts.  
 
To counteract cell death after transduction and to optimize reprogramming efficiency initial 
seeding density (1,000 vs. 5,000 cells/cm2), lentiviral load (MOI of 1 to 10), reprogramming 
medium (DMEM vs. DMEM/M199, 1 g/l vs. 5 g/l glucose, 2% vs. 10% HI-FBS), antibiotic 
selection of transduced cells (G418), and subculture were investigated for their influence. 
Irrespective of seeding density and viral load, cell death occurred in CFs cultures with varying 
dynamics, starting as early as 4 days after infection (data not shown). LeV induced toxicity, played 
a minor role, as it would be overcome 4-5 days after infection. Moreover, transduction efficiency 
with a MOI of 5 ranged approximately from 60-90% for individual viruses as stated previously 
(Figure 11). 
 
The continuous growth of the non-infected fibroblasts resulted in monolayer confluence, which 
was the major reason for the dramatic decrease in viability in the transdifferentiating cultures. 
Regular subculture and antibiotic selection of CFs after infecting with the LeV cocktail prevented 













9.3. Direct reprogramming of cardiac fibroblasts into induced cardiomyocyte like cells 
 
To initiate cardiac reprogramming to our desired cell state, CFs were infected with the LeV 
cocktail GMTMy. Two days after transduction the cells were positive for GFP (Figure 12) and all 
the transgenes were stably expressed (Figure 13). The cells were subjected to antibiotic selection 
and were regularly subcultured to prevent cell death.  
 
GMTMy induced expression of mature cardiomyocyte markers such as α-actinin, cTnT and 
myosin at both mRNA (data not shown) and protein levels starting at 1 week after infection and 
showed increased expression until 2 weeks after infection. These cells showed expression of α-
actinin, cTnT and myosin as determined by immunofluorescence (Figure 14). FACS analysis 
showed that 23% of the cells were positive for cTnT (Figure 15).   
 
In terms of morphology reprogrammed cell populations appeared heterogeneous with non-
organized cTnT positive cells and a few with sarcomeric striations. Most of the cTnT positive cells 
displayed a rounded epithelial cell-shape while a small fraction of the cells showed mature round 
like CMs patters (Figure 16). These rounded cells also displayed a proliferative capacity.  
No spontaneous contractile activity was detected within 8 weeks of observation. Mature CMs have 
low proliferation capacity, thus indicating that these epithelial-like troponin positive cells could 
be a cardiac committed precursor-like cell population – iCM precursor cells (iCMPs).  
 
Additionally, we stained the iCMPs for cardiac progenitor cell (CPC) markers, such as Cxcr4, 
Flk1, Mesp1, and Nkx2.5, as it is important that these cells show CPC markers. The iCMPs showed 
bright expression of Nkx2.5, Flk1 and Cxcr4 markers and some cytoplasmic expression of Mesp1 
(Figure 17). Mesp1 is a transcription factor and therefore the staining should be seen in the nucleus. 
However, in my hands, Mesp1 displayed an unexpected expression pattern. Further research is 
necessary, as it would also be interesting to see what role Mesp1 plays in the reprogramming 
process. 
 
All these outcomes support our assumption that the reprogrammed cells are a cardiac committed 







Figure 12: eGFP expression in cardiac fibroblasts 3 days after lentivirus cocktail GMTMy 
infection, indicating successful transduction; and control CFs with no lentivirus infection and 






Figure 13: Successful LeV transduction: Fluorescence images of CFs after transduction with 
GMTMy cocktail. The cells were stained for the transcription factors Gata4, Mef2c, Tbx5 and 
Myocd (red), DAPI (blue) to label the cell nuclei and GFP (green) for LeV. GMTMy were 






Figure 14: Direct cardiac reprogramming: Immunofluorescence images of CFs 2 weeks after LeV 
transduction showing expression of cardiac markers α-actinin, cTnT and Myosin (red), DAPI 











Figure 15: Protein expression of cardiac marker cTnT and eGFP in CFs 2 weeks after LeV 
transduction. CFs transduced with LeV cocktail GMTMy show about 93% GFP+ cells and 23.9% 















Figure 16: Immunofluorescence images 2 weeks after lentivirus transduction showing a 
heterogenous population cTnT positive cells - Rounded epithelial like cells and rod like straited 
cells stained positive for cTnT (red), DAPI (blue) to label the Nuclei and lentivirus with GFP 
(green). These results indicate a heterogeneous population of both mature and dividing cTnT+ 












Figure 17: Immunofluorescence images of CFs 2 weeks after transduction with lentiviral cocktail 
GMTMy showing expression of cardiac progenitor markers Cxcr4, Flk1, Mesp1 and Nkx2.5 (red), 





9.4. Enriched populations of iCMPs obtained by transcriptional selection  
 
Next, we sought to obtain enriched populations of these iCMPs by using the molecular beacon 
(MB) technology. The representative cardiac structural genes cardiac troponin T (cTnT) and 
myosin heavy chain (MYH6/7, α/βMHC) were expressed in the reprogrammed cells and thus were 
determined optimal candidate genes for MB design. MBs that target unique sites in MYH6/7 
mRNA in both mouse and human (55) were used.  
 
To establish an efficient MB-based transfection, it was necessary to, (1) identify an optimal ratio 
of molecular beacon to transfection reagent (TR); and (2) determine an optimal MB concentration. 
CFs 70-90% confluent were transfected with, 1:1, 1:2, 1:3 and 1:4 ratios of MB (µM) to TR (μl) 
and different MB concentrations (0.1, 1, and 10 µM). At a ratio of 1:4 MB:TR and with 1µM MB 
concentration, about 100% transfection efficiency was achieved as determined by high content 
screener image analyzer (Figures 18 and 19). Initial experiments were done with HL1 cells, 
however, HL1 cells were harder to transfect as a result the transfection efficiency was low. 
Therefore, all further establishment experiments were performed on the target cells CFs. 
 
Furthermore, we sought to determine the specificity of the MBs. In order to do this, CMs were 
isolated from mCherry transgene mice. These cells were transfected with negative control, 
positive/ delivery control, and MYH6/7 MB at the optimal working concentration and ratio. MB 
signals were analyzed by FACS. Approximately 61% of the cells were MYH6/7 positive. The  
transfection efficiency with the delivery control was about >60%, and CM detection was similar. 
Indicating that not all cells receive the beacon, but the mCherry positive cells that receive the 
beacon were MYH6/7+ (Figure 20). Thus, suggests specificity of the MYH6/7 MB for CM specific 
cells.  
 
Once the MB technology was standardized, cardiac reprogramming using LeV cocktail was 
initiated. Two weeks after GMTMy, successful reprogramming was confirmed by examining for 
cardiac marker expression. MB-based sorting yielded an MYH6/7 positive population that 
corresponded to 33+/-3.2% (Mean + SEM) of the reprogrammed cells (Figure 21). The purity of 
the sorted cells was confirmed by staining the iCMPs after sorting for cardiac markers α-actinin 
and cTnT. It was seen that 1 week after sorting the cells maintained stable cTnT and α-actinin 










Figure 18: Molecular beacon testing:  Graphical representation of MB transfection efficiency and 
MB titration as determined by high content screener image analyzer. At an MB concentration of 
1µM and at a 1:4 ratio of molecular beacon to transcription reagent, 100% transfection efficiency 







Figure 19: Molecular beacon testing:  High content screener images of CFs expressing Cy5 after 
transfection with MBs NEGC, DELC and MYH6/7. Cell nuclei were labeled with Hoechst (blue) 








Figure 20: Molecular beacon specificity: Neonatal CMs isolated from transgenic α-MHC-mCherry 
mice transfected with negative control, positive control and MYH6/7 molecular beacon and 
analyzed by flow cytometry showing mCherry and MYH6/7 (Cy5) expression. Approximately 













Figure 21: Molecular beacon-based iCMP sorting: (A) CFs 2 weeks after transduction with 
lentiviral cocktail GMTMy, transfected with 1µM MYH6/7 MB and sorted yielded approximately 
30+/-3% MYH6/7+ cells (Mean +/- SEM). CFs were transfected with NEGC and DELC as 











Figure 22: Immunofluorescence images after sorting: rounded epithelial like iCMPs expressing 
cardiac markers cTnT and α-actinin (red), DAPI to label the cell nuclei (blue) and GFP (green) for 





9.5. Global gene expression analysis of iCMPs unveil their unique transcriptome  
 
Understanding the global gene expression pattern is of paramount importance for future in vivo 
experiments as well as for clinical application of the iCMPs. Therefore, we compared the iCMPs 
after sorting to their parental CFs and mouse adult heart tissue (AHT) by RNA-Seq. The quality 
of total RNA isolates was, analyzed using the Agilent RNA 6000 Nano Kit.  
 
Principal component analysis (PCA) plots revealed that iCMPs are different from parental CFs 
and the biological replicates cluster together. However, the iCMPs move towards AHT CMs. 
These results indicate low intragroup variation and high intergroup variation indicating that they 
are in an intermediate state of cardiac development (Figure 23) 
Venn diagram revealed the differentially expressed genes and the overlap between differentially 
expressed genes (Figure 24). Three comparisons were performed, and each circle represents one 
pairwise comparison, CF versus iCMPs, CF versus AHT and iCMPs versus AHT showing 2402, 
6628 and 6197 differentially expressed gene respectively. It was observed that 720 genes were 
significant in all three comparisons. The Venn diagram shows only the overlap, regardless of the 
direction of the regulation of the genes. Therefore, it might be that some genes in the overlap 
between 2 comparisons are significant, but are upregulated in one comparison and downregulated 
in the other. 
 
This was addressed by K-Means clustering and Gene Ontology (GO) analysis. K-Means clustering 
of the differentially expressed genes was performed to determine the genes that are upregulated 
and downregulated generating six gene clusters – cardiac development, cell proliferation, cardiac 
metabolism/ contraction, embryogenesis/ morphogenesis, and metabolism.  
We found that iCMPs show upregulation of genes associated with cardiac development, 
metabolism, contraction compared to CF. Downregulation of genes associated with cell-
proliferation was observed in iCMPs in comparison to their parental CFs. However, in AHT 
compared to iCMPs, cell proliferation genes were further downregulated, indicating that the 
iCMPs still maintain some cell proliferation abilities though lower than in CF. Morphogenesis 
genes were upregulated in iCMP versus CF, but were downregulated in AHT. Genes associated 
with oxidative metabolism were upregulated in AHT and downregulated in both iCMPs and CF 





Evaluation of a selected gene set showed an upregulation of transcription factors that were 
overexpressed - Gata4, Mef2c, Tbx5, Myocd as well as transcription factors like Hand2 and Mef2a 
compared to CF indicating on-set of cardiac development. Downregulation of proliferation genes 
such as Ki67, Plk1, Mcm2 were seen in iCMPs compared to CF, moving them closer to AHT. 
However, proliferation was still maintained in iCMPs compared to AHT. Cardiac progenitor gene 
PDGFRa was slight upregulated in iCMPs versus CF. iCMPs compared to CF showed 
upregulation of cardiac contractile gene such as cTnT as well as and ion channel genes like Kcnh2, 
Scn5A, Ryr1/2/3. Finally, as expected downregulation of certain non-myocyte genes such as 
Col3A1 and Vim was seen (Figure 26). 
 
qPCR studies for selected genes were performed to validate our gene expression findings. To 
understand the gene expression pattern and developmental state of the iCMPs in-depth, we 
additionally compared them to mouse embryonic heart tissues (mEH) and mouse neonatal heart 
tissue (mNH) (Figures 27). As seen in the RNA-Seq data, there was upregulation of TFs (Gata4, 
Mef2c, Tbx5 and Myocd in iCMPs compared to CFs. There was also expression of Mef2a and 
Hand2 in iCMPs. CPC marker PDGFRa expression was observed in iCMPs, slight expression of 
this was also seen in CF. No Nkx2.5 expression was observed similar to RNA-Seq, one explanation 
could be that mRNA production stops, when enough protein is there. Non-myocyte marker VIM 
expression was downregulated in iCMPs compared to CF. Additionally, expression of cardiac 
markers such as cTnT, Myh6 was observed.  
Gene expression levels in iCMPs are more comparable to mouse embryonic heart tissue rather 

















Figure 23: Global transcriptome analysis of iCMPs: Principal component analysis (PCA) plots 
reveal low intra group variation and high inter group variation. The iCMPs are different from the 








Figure 24: Global transcriptome analysis of iCMPs: Venn diagram revealing the differentially 
expressed genes and the overlap between differentially expressed genes in CFs versus AHT, CFs 












Figure 25: K Means clustering and Gene Ontology (GO) analysis: Heat map showing genes that 
have been categorized into clusters of genes that were upregulated and down regulated in the 
iCMPs, compared to their parental CFs and AHT. iCMPs show upregulation of genes associated 
with cardiac development, metabolism, contraction and embryogenesis while they showed down 
regulation of genes associated to cell-proliferation and metabolism when compared to their 






Figure 26: Evaluation of selected gene sets: iCMPs showed upregulation of genes associated with 
transcription factors and cardiac contractile proteins such as cTnT. They also showed upregulation 
of genes associated to ion channel in comparison to CFs. In contrast, gene encoding non-myocyte 







Figure 27: Gene expression analysis by qPCR in iCMPs, CFs, mouse adult heart, mouse 
embryonic heart and mouse neonatal heart tissue. transcription factors: Gata4, Mef2c, Mef2a, 
Tbx5, Myocd and HAND2; progenitor markers: Nkx2.5, PDGFRa; non-myocyte and proliferation 





9.6. Long term expansion of iCMPs does not affect proliferation while maintaining a stable 
phenotype  
 
To monitor proliferation and phenotype stability of iCMPs after sorting was monitored in order to 
determine the ability to generate large scale cell products and to show the regenerative potential 
long term. iCMPs were maintained in culture over serial passages while cell growth and cardiac 
gene expression were assessed. These MYH6/7 positive cells were highly viable as determined by 
trypan blue staining and cell counting. The iCMPs proliferated up to 57X fold (Figures 28A), that 
is 22 population doublings in 28 days. With a starting cell number of 50,000 cells we could obtain 
3x10^11 cells in 28days (Figures 28B). They maintained a high degree of similarity in growth rate 
between passages. However, all experiments with these cells were performed at passages 2-4. 
 
MB-based analysis of the iCMPs 1 week after sorting revealed that the MYH6/7+ population 
dominated the total population (more than 80%). However, over time the positive fraction 
decreased to about 40-50% in week 2. CF contamination could be one reason, which could be 
reduced with G418-based antibiotic selection. However, the effect was relatively low (about 10%) 
to a purity of 65% (Figures 29 and 30).  Thus, the contribution of CF impurity was low.  
 
Cells losing iCMP phenotype could be another possible reason for this. Therefore, we sought to 
counteract this by supplementing the iCMPs with factors that support the maintenance of a 
cardiomyogenic phenotype. We tested a set of established cardiac specification factors - Ascorbic 
acid, BMP4+FGF, BMP4+FGF+VEGF and VEGF+FGF. Ascorbic acid addition to iCMP culture 
medium CRM showed increased MYH6/7 expression in week 2 (99.5%) as compared to the 
addition of BMP4+FGF (65%), BMP4+FGF+VEGF (74%) or VEGF+FGF (76%) and this trend 
continued to week 3 of iCMPs in culture (Figures 29 and 30).   









Figure 28: Cell proliferation – iCMPs post sorting were highly viable they proliferated (A) up to 
57X folds in 28 days and (B) up to 3x10^11 cells starting from 50,000 cells in 28 days. 
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Figure 29: Stability of iCMPs 2 weeks after sort: Reduced MYH6/7 expression was observed in 
iCMPs 2 weeks after sort and when cultured in CRM. Addition of ascorbic acid was seen to best 























Figure 30: Stability of iCMPs 3 weeks after sort: Ascorbic addition helped preserve a stable iCMP 











9.7. Differentiation potential of iCMPs  
 
We have a cardiac progenitor population that can proliferate, but if true regeneration is to take 
place, these cells must be able to differentiate into cardiomyocytes. Therefore, to investigate the 
differentiation capacity of iCMPs, a couple of established CPC differentiation strategies were 
explored. iCMPs theoretically have the potential to differentiate into any of the three main cell 
types found in the heart – cardiomyocytes, smooth muscle cells, or endothelial cells. Thus, we 
investigated the expression of proteins associated with each of these cell type. 
 
iCMPs, when maintained in serum-free differentiation medium (SFDM) for 20 days with the initial 
supplementation of the Wnt inhibitor IWP2, showed a slight change in morphology and very low 
cardiac marker expression. After 20 days in culture with SFDM cells showed smooth muscle 
marker expression (αSMA), but no endothelial marker (CD31) expression (Figure 31). Similarly, 
iCMPs when maintained in cardiac differentiation medium (CDM) for 20 days with the initial 
supplementation of the Wnt inhibitor IWR1, showed smooth muscle marker (αSMA) expression 
(Figure 31).  
Additionally, we chose to investigate the influence of cardiac extracellular matrix cECM in 
combination with differentiation media on our iCMPs. Our lab (68, 69) has chosen to investigate 
the use of cECM as a hydrogel and therefore has developed a method for producing a cECM-based 
coating using limited chemical processing. Its use as a hydrogel can create a more cardiac-specific 
environment to maintain iCMP phenotype or facilitate differentiation. cECM maintained low 
cardiac marker expression and showed αSMA expression in both SFDM and CDM, but no CD31 
expression (Figure 32).   
 
Apart from Wnt inhibition, 5-Azacytidine and TGFß are known to promote cardiomyogenic 
differentiation in ESCs and are critical for the expression of cardiac-specific markers. It has been 
shown that CPC when cultured in differentiation medium (DM) and treated with 5-Azacytidine 
and TGFß, resulted in beating CMs (62). iCMPs when treated similarly cells showed change in 
morphology, from rounded epithelial patterns to rod shaped, long straited cells as seen in 
immunofluorescence staining. Cells expressing the cardiac marker α-actinin showed a dense 
sarcomeric expression pattern. cTnT and myosin positive cells showed formation of sarcomeric 




CD31 expressions were seen (Figures 33 and 34). No spontaneous contraction was observed up to 
20 days in differentiation medium.  
 
Additional mechanical, electrical and paracrine stimulation was provided to proliferative iCMPs 
to induce differentiation, by culturing them with either iPSC-derived CMs or mouse neonatal α-
MHC-mCherry CMs. The iPSC-CMs were labeled with the cell labeling dye red to distinguish 
them from the iCMPs. In co-culture set up beating patches of red and green cells were observed 
(Supplemental Video) via time-lapse imaging. However, despite cell labelling, it was not clear if 
the iCMPs were contracting themselves or if it was moved by the contracting CMs. The results 





Figure 31: Differentiation potential of iCMPs: iCMPs cultured for 20 days on Matrigel in SFDM, 
on gelatin in CDM, and on gelatin in CRM showing low levels of expression of cardiac markers 
α-actinin, cTnT and Myosin; smooth muscle marker αSMA; and no endothelial marker CD31 




Figure 32: Influence of cECM on iCMPs: iCMPs cultured for 20 days on cECM in SFDM, CDM, 
and in CRM showing low expression of cardiac markers α-actinin, cTnT and Myosin; smooth 
muscle marker αSMA; and no endothelial marker CD31 (red). Cells were stained with DAPI (blue) 
to label the Nuclei. Scale bars = 500µm.  
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Figure 33: iCMP differentiation with 5-Azacytidine and TGFß supplement: Cells showed a dense 
sarcomeric expression pattern of cardiac markers α-actinin, cTnT and myosin, and smooth muscle 
marker αSMA (red), DAPI (blue) to label the cell nuclei and GFP (green). No endothelial marker, 






 Figure 34: iCMP differentiation: Immunofluorescence images of iCMPs at a 40X magnification 
showing change in morphological characteristics. Cardiac markers α-actinin, cTnT, Myosin, 
smooth muscle markers αSMA (red), DAPI (blue) to label the cell nuclei and GFP (green). No 






9.8. Transplantation of iCMPs into infarcted heart improves cardiac function 
 
The ultimate goal of this study was to evaluate the functional and regenerative potential of the 
iCM precursor cells in the native heart environment after injury. Therefore, after demonstrating 
that iCMPs expanded long term and maintained a cardiac committed phenotype, we wished to 
extend the approach to the native heart environment.  
 
To do so, stocks of iCMPs were produced in large scale. iCMPs, after reprogramming and sorting, 
were expanded to produce cell doses of 500,000 cells/mouse. eGFP-CFs were produced and 
treated in ways similar to the iCMPs except for antibiotic selection. eGFP-CFs were obtained by 
infecting CFs with LeV eGFP and cell-sorted based on their GFP signal. 90% of the infected cells 
were GFP+ (Figure 35). After sorting the eGFP-CFs were expanded to produce the required cell 
doses of 500,000 cells/mouse. Cells were trypsinized, thoroughly washed and resuspended in PBS 
for intramyocardial injections. All cells used were of passage 3-5.  
 
MI was induced by ligating the left anterior descending artery. Immediately thereafter, the mice 
received intramyocardial injections with either iCMPs or eGFP-CFs or PBS. Cardiac function 
(Table 4) was monitored and calculated by echocardiography at week 2, 4 and 6 after treatment.  
 
The echocardiography analysis showed improved left ventricular function in iCMP-treated 
animals compared to the controls eGFP-CFs and PBS. The left ventricular ejection fraction 
(LVEF) was improved as early as 2 weeks after iCMP injection and was maintained until weeks 6 
in comparison to the controls. LVEF of iCMP-treated animals were 38% ± 6.9, whereas the PBS 
treatment had an LVEF of 20% ± 4.2 and eGFP-CF treatment had an LVEF of 17% ± 4.6 at week 
6 (Figure 36 and 37). Left ventricular fractional shortening (LVFS) of the short axis of the heart 
was 22% ± 3 for iCMPs, 16% ± 2 for PBS and 9% ± 2.2 for eGFP-CF-treated animals at week 6 
(Figure 38). The sham groups had an LVEF of 66% ± 4.4 and LVFS of 36% ± 2.4. 
 
Supporting the LVEF and LVFS outcome, an improvement in stroke volume (SV) was observed 
in mice group treated with iCMPs compared to the control groups (Figure 39).  SV of iCMP-
treated animals at week 6 were 47% ± 6.8, while the PBS treatment had an SV of 29% ± 6 and 




Additionally, there was less dilation of the hearts when treated with iCMPs as seen in EDV and 
ESV plots (data not shown). In line with these outcomes, an improvement in cardiac output of the 
heart was observed showing, 20% ± 3.4 for iCMPs, 13% ± 2.6 for PBS and 11% ± 1.6 for eGFP-
CF-treated animals at week 6 (Figure 40). Besides, no abnormal growth was observed up to 6 
weeks in the mice hearts.  
These results strongly indicated that iCMPs can improve and restore left ventricular function and 
attenuated remodeling after ischemic myocardial injury.  
 
Echocardiography read outs 
Left ventricular Ejection fraction 
(LVEF) 
Percentage of blood leaving the heart  
= SV/EDV * 100  
Left ventricular Fractional 
shortening (LVFS) 
The fraction of any diastolic dimension that is lost in 
systole  
= end-diastole dimension minus end-systole dimension 
(EDD-ESD) 
Left ventricular wall thickness  
(LVPWd) 
Left ventricular posterior wall thickness at end-diastole  
Stroke volume (SV) 
Volume of blood pumped out  
= end-diastole minus end-systole  
Cardiac output (CO) Volume blood pumped out per minute  
End diastole volume (EDV) 
Volume of blood in the right and/or left ventricle 
at end load or filling in 
End systole volume (ESV) 
Volume of blood in a ventricle at the end of contraction 
and the beginning of filling.  
 







Figure 35: Cell preparation for animal experiments: (A) Sorting of eGFP-CFs based on their GFP 
signal post transduction of CFs with LeV-eGFP, 90% of the cells were positive for GFP. (B) MB-
based sorting of iCMPs 2 weeks after infection with lentiviral cocktail GMTMy yielded 37% 






Figure 36: Left ventricular ejection fraction: iCMP treatment after MI in a mice model, showed 
improvement in left ventricular ejection fraction as seen at week 2, 4 and 6 compared to PBS and 
eGFP-CFs. The boxplots indicate interquartile range (box), median (line), range (min to max) and 










Figure 37: Left ventricular ejection fraction: Left ventricular ejection fraction shown overtime at 
week 2, 4, and 6 as mean ± SEM, * ◊ P<0.05 iCMP vs. CF/PBS, + P<0.001 iCMP vs. Sham. 






Figure 38: Left ventricular fractional shortening: iCMP treatment after MI in a mice model, 
showed improvement in left ventricular fractional shortening as seen at week 2, 4 and 6 compared 
to PBS and eGFP-CFs. The boxplots indicate interquartile range (box), median (line), range (min 











Figure 39: Stroke Volume: An improvement in stroke volume was observed in mice treated with 
iCMPs by week 6 compared to PBS and eGFP-CFs. Data shown as mean ± SEM ANOVA, 















Figure 40: Cardiac output: Cardiac output observed in mice treated with iCMPs, PBS, CFs or 
SHAM at week 6. An improvement in CO was observed in iCMPs compared to CF and PBS 







10. DISCUSSION  
 
Improving direct cardiac reprogramming 
 
iCM have come across as an appealing CM-like cell for disease modeling, drug testing and also 
potential therapeutic application in patients to repair or regenerate the injured heart directly 
through the formation of newly transplanted tissue. When Ieda et al. first reported direct cardiac 
reprogramming with GMT in 2010, the reprogramming efficiency of generating fully 
reprogrammed functional iCMs although promising was very low, few iCMs (0.01–0.1% of total 
cells) showed spontaneous contractions. Huge efforts are underway ever since, to improve the 
reprogramming efficiency, including modifications of stoichiometry, transcription factors, small 
molecules, micro-RNAs and epigenetic factors (3-24). Wang et al. generated polycistronic vectors, 
with a possible combination of the three factors in a single transgene to test modifications of 
stoichiometry. Their findings revealed that a high level of Mef2c and low levels of Gata4 and 
Tbx5, enhanced cardiac reprogramming, consistent to the findings by Hirai et al. that increasing 
the transcriptional activity in Mef2c is critical for successful reprogramming for mature iCMs (31, 
37). Besides TFs and delivery vectors, a combination of specific microRNAs (miR-1, miR-133, 
miR-208, and miR-499) and silencing of fibroblast signatures was tested (29, 36). However, 
despite all these efforts iCM reprogramming efficiency were still low. Moreover, mature iCMs 
have little or no proliferative capacity, thus, making the regeneration of the heart a difficult 
process, as the low number of iCMs are insufficient to regenerate heart tissue.  
 
We are therefore in need of a more clinically relevant cardiomyogenic cell type that,  
- Has the ability to proliferate  
- Is cardiac committed - therefore can generate functional cardiac muscle and vasculature 
- Is safe and doesn’t create tumors  
- Improves heart function after injury  
 
In this study, I show that - GMT along with Myocd (My) reprogrammed the cardiac fibroblasts 
towards a phenotype of proliferative, induced cardiomyocyte precursors (iCMPs). The cTnT 
expressions were strikingly high as seen according to RNA-Seq and according to proteins levels. 
We were able to purify the iCMPs at high efficiency and specificity from reprogramming cultures 




A distinct feature of this iCMPs is their ability to proliferate while maintaining similar morphology 
and gene expression pattern. For cell-based therapies, it is highly desirable to generate expandable 
sources of committed cells. During iCM reprogramming cell proliferation is suppressed and CM 
differentiation-specific genes are activated (70). In contrast, global transcriptome analysis and 
protein expression patterns revealed that iCMPs represent an intermediate state of cardiomyocyte 
development with preserved mitotic capacity as well as cardiomyogenic lineage commitment.  
 
Different kinds of cardiac progenitor populations have been identified to date, such as Flk1+, 
Mesp1+, Isl1+, Sca1+, and Nkx2.5+ (71-76). The iCMPs however unlike all other CPCs express 
a couple of progenitor markers such as Cxcr4, Flk1, Mesp1, PdgfRa and Nkx2.5. These results 
indicate that our iCMPs similar to the endogenous CPCs population are a mixed cell pool 
expressing multiple cardiac committed progenitor markers, which could be beneficial for in vivo 
cell transplantation and cardiac regeneration.   
 
It has been demonstrated that cardiac progenitor cells (CPCs) represent effective cell-based 
therapy for MI. However, endogenous CPCs are not sufficient for regeneration after injury and the 
procedure of harvesting for expansion are invasive and could cause more injury to patients. The 
generation of induced CPCs or iCMPs thus seems attractive. Two groups have reported on the 
induction of expandable CPCs from mouse fibroblasts with the combination of transcription 
factors and small molecules (Table 5). Zhang et al. found that the induced CPC (Flk1+ PdgfR⍺+ 
population) could be generated from mouse fibroblasts with overexpressing Sox2, Klf4, Oct4, and 
c-Myc. Lalit et al. adopted a straightforward approach to reprogram fibroblasts into Nkx2.5+ 
iCPCs through lineage-specific transcription factors Mesp1, Tbx5, Gata4, Nkx2.5, and Baf60c. 
However, one of the primary problems of long-term cell culture of transdifferentiated cells is the 
overgrowth by contaminating fibroblasts and residual fibroblast identity. Zhang et al, reported 
BMP4, Activin A, CHIR99021 (GSK3beta inhibitor) and SU5402 (FGF, VEGF, and PDGF 
inhibitor) stimulation for stable maintenance. While Lalit et al. state that the addition of (leukemia 
inhibitory factor) LIF and BIO stimulation were necessary for stable expansion and maintenance 
of iCPCs.  
 
In case of the iCMPs MB-based FACS sorting after reprogramming circumvented fibroblast 
contamination and growth. Additionally, I found that ascorbic acid supplementation maintained a 




in several studies proving its role in cardiogenesis crucial. Ascorbic acid induces pluripotent stem 
cells at different phases of differentiation, it induces cardiac progenitor specification and 
proliferation and it is known to induce cardiomyocyte maturation at both the structural and 






Table 5: Generation of cardiac progenitor and precursor cells via direct reprogramming 
  
Reference Zhang et al. (60) Lalit et al. (78) This study  
Starting cell type MEF, TF CF, TF CF 
Transcription 
factors  
Sox2, Klf4, Oct4, 
c-Myc 
Mesp1, Tbx5, Gata4, 
Nkx2.5, Baf60c 









BMP4, Activin A, 
CHIR99021, SU5402 
(BACS) 
LIF, BIO Ascorbic acid 
CPC Marker 
expression 
Flk1, PdgfR⍺  Nkx2.5, Irx4 




                -                 - 
cTnT, Myosin,   
α-actinin 
Purification 





Myh6/7 based FACS 
sorting 
Proliferation  
>1010 fold expansion 
in 18 passages 
                 - 




















function – LVEF, 




Modification of signaling pathways and environmental cues for CM differentiation  
 
iCMPs with the addition of 5-Azacytidine and TGFß induced increased expressions of cardiac and 
contractile genes such as cTnT and α-actinin, additionally, they showed an assembly of sarcomeric 
bundles on the protein level. Which is in line to studies by Goumns et al. that 5-Azacytidine and 
TGFß enhance cardiomyocyte differentiation of cardiomyocyte progenitor cells (hCMPCs) from 
human heart tissue and resulted in functional beating CMs (62, 79).   
Consistent with this Gearhart et al. showed that inhibition of fibroblast-related signaling pathways, 
such as transforming growth factor-β (TGFβ), enhanced cardiac reprogramming efficiency and 
maturation through silencing of fibroblast signatures (46). 
 
In our hands, an effort to obtain mature contracting iCMs from iCMPs using Wnt inhibition as 
reported by Zhang et al. and Li et al. (60, 61) was not successful. A possible factor influencing the 
maturation of iCMPs to iCM is the timing of Wnt inhibition. Previous work examining the effects 
of Wnt/β-catenin signaling on mouse ES cell differentiation into cardiomyocytes deduced that this 
pathway exhibits developmental stage-specific, biphasic, and antagonistic effects on 
cardiomyogenesis and hematopoiesis/vasculogenesis (16, 60).  
Activation of the Wnt/β-catenin pathway in the early phase of development enhanced ESC 
differentiation into CMs, but the reverse is observed in the late phase after embryonic body 
formation (80). The timely activation and deactivation of particular genes and signaling molecules 
have repeatedly been shown to have a strong influence on cell fate decisions during development. 
Therefore, it may be necessary to refine the timing and duration of Wnt inhibition to efficiently 
promote cardiomyocyte differentiation.  
 
No spontaneous contraction was observed up to 20 days in the differentiation conditions. However, 
in an in vitro heart model such as the co-culture set up beating patches of red and green cells were 
observed. Thus indicating that upon stimuli, the iCMPs could contract. It would be interesting to 
investigate this further.  
 
Environmental cues, such as extracellular matrix (ECM), 3D hydrogels and scaffolds are also 
important for cardiac maturation. There are wide varieties of hydrogel materials and delivery 




example, studies have shown that using a microgroove substrate or using a 3D fibrin hydrogel 
culture enhances reprogramming efficiency (81, 82).   
We chose to investigate the influence of cECM based-hydrogel in combination with differentiation 
media on our iCMPs. Its use as a hydrogel can create a more cardiac-specific environment to 
maintain iCMP phenotype or facilitate differentiation. In our experiments, the use of cECM 
maintained cardiac marker expression on protein level indicating its supportive effect on the 
differentiation. Our lab has previously shown that cardiac lineage commitment was favored when 
ESCs or iPSCs were grown on cECM (83). In the future, it would be interesting to investigate the 
influence of cECM on transduction and reprogramming efficiency as well, proving a cardiac 
environment from the start.   
 
The iCMPs are a heterogeneous population of cells that express cardiac progenitor genes such as 
Cxcr4, Flk1, Mesp1, Nkx2.5; cardiac mesoderm genes such as Gata4, Tbx5, Tbx20, Mef2c, 
Mef2a, HAND2; and mature cardiac genes such as cTnT and α-actinin as seen in 
immunofluorescence staining and RNA-Seq. This could also explain why at present, none of the 
Wnt differentiation stimuli singularly is sufficient to induce complete maturation equivalent to that 
of adult CMs. A combination of stimuli may bypass the problems associated with iCMP 
differentiation.  
 
Nevertheless, cardiomyocytes are not the only cell type required for heart regeneration. 
Cardiogenesis requires the generation of diverse muscle and nonmuscle cell lineages: atrial and 
ventricular cardiomyocytes, smooth muscles cells, endothelial cells, cells of the coronary arteries 
and veins, endocardial cells, valvular components, and connective tissue. One of the major sources 
of heart cell precursors in the embryo is the cardiogenic mesoderm. The cardiogenic mesoderm, 
with distinct contributions to the mature heart, ultimately forms the majority of the working 











Cardiac reprogramming in vivo  
 
To examine the efficiency of iCMPs for cardiac regenerative medicine, we tested the potency of 
iCMPs in an adult mouse heart. iCMPs were transplanted intramyocardialy into a mice model of 
MI, resulting in preservation of cardiac function. iCMP treatment showed improvement in LVEF 
and LVFS whereas PBS and CF treated groups showed a decline. Similarly, iCPC transplantation 
studies by Zhang et al. and Lalit et al. have shown improvement in heart function and improved 
survival after treatment. With iCMPs treatment cardiac functional improvement was seen at an 
early stage (2 weeks) and was maintained long term in mice after acute myocardial injury (6 
weeks). This improvement may be a result of iCMP engraftment, differentiation to CMs to restore 
heart contractility, contributing to blood-vessel formation and integration into surrounding tissues 
(84). Similarly, Zhang et al. showed that iCPC induced a sudden increase in heart function as early 
as 3days after treatment, which then reduced at week 2 up to week 4 and was then maintained 
consistent up to week 12. 
 
Other than LVEF and LVFS our results showed an improvement in LVPWd and CO as compared 
to the control groups. However, the CO values were slightly higher in iCMPs than that of SHAM. 
As part of the tissue dies and loses function after MI the remaining heart tissue overcompensates 
resulting in hypertrophy, which might explain the iCMPs CO.  
 
In vivo differentiation may have been possible due to additional environmental cues such as ECM 
and/or secreted proteins, exosomes or paracrine effect. The discovery of cardiovascular precursor 
cells in mammalian embryos, human hearts, as well as in intermediate stages of differentiation of 
ESCs and iPSCs offers exciting opportunities in the field of cardiac translational medicine. 
Cardiovascular precursors offer an advantage over iCMs, as they might be able to proliferate and 
differentiate into diverse mature cardiovascular lineages, thus contributing to both 
remuscularization and revascularization (84). 
 
Ieda et al. in their first study transplanted GMT overexpressing CFs one day after viral transduction 
and showed that within 2 weeks they were able to detect the injected cells and these cells also 
expressed α-actinin and had sarcomeric structures; while no functional improvement was reported 
(27).  In contrast, Chen et al showed that transplantation of GMT overexpressing CFs into injured 





Ever since, alternate to cell therapy, other groups have demonstrated that gene transfer of 
appropriate reprogramming factors can better improve cardiac function and suppress fibrosis after 
MI (41, 42, 86-88). It is understandable that gene transfer might be preferred, as engraftment of 
transplanted cells could be a major limitation for cardiac cell therapies. However, different routes 
such as cells immobilized on bioengineered scaffolds or cECMs could be an option to overcome 
this.  Moreover, ex vivo transduction circumvents in vivo off-target effects, an immune response 
to viral vectors and it allows the cells to be examined and tested for insertional mutagenesis. 
Moreover, large amounts of an individual’s fibroblasts can be grown from a cardiac biopsy or skin 
biopsy in vitro for transduction with the defined factors, followed by expansion to produce millions 
of cells and delivery of cells to damaged hearts. Most importantly, it allows cell expansion and off 
the shelf storage.  
 
This study shows that iCMPs can improve and restore left ventricular function after acute 
myocardial injury. Further studies are underway testing the use of cECM patch in aiding iCMP 
engraftment and enhancing functional improvement. As an alternative to just intramyocardial 
iCMP injections, we plated iCMPs on to cECM patches and cultured them overnight in CRM 
allowing the cells to adhere to the cECM surface. The cECM patches with cells were sutured on 
to the mice heart after induction of MI. The mice were monitored regularly.  However, this study 








In summary, cardiac reprogramming is a promising strategy for cardiac cell therapy and there has 
been significant progress in the past years to increase the efficiency and function of iCMs.  
 
In this project, we were able to generate a cardiac committed proliferative cell type – iCMPs by 
direct reprogramming of cardiac fibroblasts, using the cardiac transcription factors Gata4, Mef2c, 
Tbx5, Myocd (GMTMy). The iCMPs are a heterogeneous population of cells with high cardiac 
troponin expression along with multiple cardiac progenitor markers such as Cxcr4, Flk1, Mesp1, 
and Nkx2.5. Next, pure iCMP populations were obtained by transcriptional selection with 
MYH6/7-targeting molecular beacons.  
 
iCMPs can be expanded to yield therapeutic cell doses. Structural abilities such as sarcomeric 
formations upon 5-Azacytidine addition were ascertained. Furthermore, they exert therapeutic 
benefits in vivo - Serial transthoracic echocardiographic analyses revealed long term functional 
benefits such as improvement in heart function after MI in mice treated with iCMPs compared to 
the no treatment and control groups.  
 
Taken together, iCMPs generated via direct cellular reprogramming followed by transcriptional 
selection display a phenotype compatible with an intermediate state of cardiogenic development 
and beneficially aid post-infarct myocardial remodeling in a rodent model. Thus, cardiac 
regeneration with iCMPs might be a potential cell therapy option for heart diseases. 
 
 In the near future, to translate the iCMP strategy into clinical studies, a shifted focus on human 









12. LIST OF REFERENCE 
 
1. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling 
in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc 
Imaging. 2011;4(1):98-108. 
2. Awada HK, Hwang MP, Wang Y. Towards comprehensive cardiac repair and regeneration 
after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials. 2016;82:94-
112. 
3. Medical Advisory S. Left ventricular assist devices: an evidence-based analysis. Ont 
Health Technol Assess Ser. 2004;4(3):1-69. 
4. Karimov JH, Sunagawa G, Horvath D, Fukamachi K, Starling RC, Moazami N. Limitations 
to Chronic Right Ventricular Assist Device Support. Ann Thorac Surg. 2016;102(2):651-8. 
5. Toyoda Y, Guy TS, Kashem A. Present status and future perspectives of heart 
transplantation. Circulation journal : official journal of the Japanese Circulation Society. 
2013;77(5):1097-110. 
6. Lin Z, Pu WT. Strategies for cardiac regeneration and repair. Science translational 
medicine. 2014;6(239):239rv1. 
7. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S. Evidence 
for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102. 
8. Wang WE, Li L, Xia X, Fu W, Liao Q, Lan C, et al. Dedifferentiation, Proliferation, and 
Redifferentiation of Adult Mammalian Cardiomyocytes After Ischemic Injury. Circulation. 
2017;136(9):834-48. 
9. Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for 
chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 
2016;12:CD007888. 
10. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. 
11. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from 
mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651-4. 
12. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH. Cardiomyocyte differentiation of 




13. Hartman ME, Dai DF, Laflamme MA. Human pluripotent stem cells: Prospects and 
challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. 
Advanced drug delivery reviews. 2016;96:3-17. 
14. Talkhabi M, Aghdami N, Baharvand H. Human cardiomyocyte generation from pluripotent 
stem cells: A state-of-art. Life Sci. 2016;145:98-113. 
15. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, et al. Chemically defined 
generation of human cardiomyocytes. Nature methods. 2014;11(8):855-60. 
16. Burridge PW, Keller G, Gold JD, Wu JC. Production of de novo cardiomyocytes: human 
pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012;10(1):16-28. 
17. Sheehy SP, Pasqualini F, Grosberg A, Park SJ, Aratyn-Schaus Y, Parker KK. Quality 
metrics for stem cell-derived cardiac myocytes. Stem cell reports. 2014;2(3):282-94. 
18. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts 
fibroblasts to myoblasts. Cell. 1987;51(6):987-1000. 
19. Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic cell lines into 
eosinophils, thromboblasts, and erythroblasts. Genes & development. 1995;9(10):1250-62. 
20. Xie H, Ye M, Feng R, Graf T. Stepwise reprogramming of B cells into macrophages. Cell. 
2004;117(5):663-76. 
21. Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF. 
Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. 
Nature medicine. 2005;11(3):271-6. 
22. Zheng JL, Gao WQ. Overexpression of Math1 induces robust production of extra hair cells 
in postnatal rat inner ears. Nat Neurosci. 2000;3(6):580-6. 
23. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R. Revisiting Cardiac 
Cellular Composition. Circulation research. 2016;118(3):400-9. 
24. Ruskoaho VTaH. Cardiac fibrosis in myocardial infarction-from repair and remodeling to 
regeneration. 2016 Jun 21. 
25. Byun J, Huh JE, Park SJ, Jang JE, Suh YL, Lee JS. Myocardial injury-induced fibroblast 
proliferation facilitates retroviral-mediated gene transfer to the rat heart in vivo. The journal of 
gene medicine. 2000;2(1):2-10. 
26. Aydin B, Mazzoni EO. Cell Reprogramming: The Many Roads to Success. Annu Rev Cell 




27. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG. Direct 
reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 
2010;142(3):375-86. 
28. Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, et al. Conversion of mouse 
fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nature cell biology. 
2011;13(3):215-22. 
29. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K. MicroRNA-
mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. 
Circulation research. 2012;110(11):1465-73. 
30. Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, Ravens U. A new approach to 
transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. 
Journal of molecular and cellular cardiology. 2012;53(3):323-32. 
31. Hirai H, Katoku-Kikyo N, Keirstead SA, Kikyo N. Accelerated direct reprogramming of 
fibroblasts into cardiomyocyte-like cells with the MyoD transactivation domain. Cardiovascular 
research. 2013;100(1):105-13. 
32. Addis RC, Ifkovits JL, Pinto F, Kellam LD, Esteso P, Rentschler S. Optimization of direct 
fibroblast reprogramming to cardiomyocytes using calcium activity as a functional measure of 
success. Journal of molecular and cellular cardiology. 2013;60:97-106. 
33. Smith AW, Hoyne JD, Nguyen PK, McCreedy DA, Aly H, Efimov IR. Direct 
reprogramming of mouse fibroblasts to cardiomyocyte-like cells using Yamanaka factors on 
engineered poly(ethylene glycol) (PEG) hydrogels. Biomaterials. 2013;34(28):6559-71. 
34. Christoforou N, Chellappan M, Adler AF, Kirkton RD, Wu T, Addis RC. Transcription 
factors MYOCD, SRF, Mesp1 and SMARCD3 enhance the cardio-inducing effect of GATA4, 
TBX5, and MEF2C during direct cellular reprogramming. PloS one. 2013;8(5):e63577. 
35. Xie M, Cao N, Ding S. Small molecules for cell reprogramming and heart repair: progress 
and perspective. ACS chemical biology. 2014;9(1):34-44. 
36. Muraoka N, Yamakawa H, Miyamoto K, Sadahiro T, Umei T, Isomi M. MiR-133 promotes 
cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. The 
EMBO journal. 2014. 
37. Wang L, Liu Z, Yin C, Asfour H, Chen O, Li Y. Stoichiometry of Gata4, Mef2c, and Tbx5 





38. Fu JD, Stone NR, Liu L, Spencer CI, Qian L, Hayashi Y, et al. Direct Reprogramming of 
Human Fibroblasts toward a Cardiomyocyte-like State. Stem cell reports. 2013;1(3):235-47. 
39. Wada R, Muraoka N, Inagawa K, Yamakawa H, Miyamoto K, Sadahiro T. Induction of 
human cardiomyocyte-like cells from fibroblasts by defined factors. Proceedings of the National 
Academy of Sciences of the United States of America. 2013;110(31):12667-72. 
40. Nam YJ, Song K, Luo X, Daniel E, Lambeth K, West K. Reprogramming of human 
fibroblasts toward a cardiac fate. Proceedings of the National Academy of Sciences of the United 
States of America. 2013;110(14):5588-93. 
41. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L. In vivo reprogramming of 
murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012;485(7400):593-8. 
42. Mathison M, Gersch RP, Nasser A, Lilo S, Korman M, Fourman M. In vivo cardiac cellular 
reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium 
with vascular endothelial growth factor. J Am Heart Assoc. 2012;1(6):e005652. 
43. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target 
in myocardial remodeling and failure. Annual review of pharmacology and toxicology. 
2005;45:657-87. 
44. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac 
fibroblasts. Cardiovascular research. 2005;65(1):40-51. 
45. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J 
Physiol Heart Circ Physiol. 2006;291(3):H1015-26. 
46. Ifkovits JL, Addis RC, Epstein JA, Gearhart JD. Inhibition of TGFbeta signaling increases 
direct conversion of fibroblasts to induced cardiomyocytes. PloS one. 2014;9(2):e89678. 
47. Hirai H, Kikyo N. Inhibitors of suppressive histone modification promote direct 
reprogramming of fibroblasts to cardiomyocyte-like cells. Cardiovascular research. 
2014;102(1):188-90. 
48. Talkhabi M, Pahlavan S, Aghdami N, Baharvand H. Ascorbic acid promotes the direct 
conversion of mouse fibroblasts into beating cardiomyocytes. Biochemical and biophysical 
research communications. 2015. 
49. Morez C, Noseda M, Paiva MA, Belian E, Schneider MD, Stevens MM. Enhanced 





50. Wang L, Liu Z, Yin C, Zhou Y, Liu J, Qian L. Improved Generation of Induced 
Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and 
Tbx5. J Vis Exp. 2015(105). 
51. CHOOI MAY LAI YKYL, and P. ELIZABETH RAKOCZY. Adenovirus and AAV 
vectors.pdf. 2002. 
52. Nitin N, Santangelo PJ, Kim G, Nie S, Bao G. Peptide-linked molecular beacons for 
efficient delivery and rapid mRNA detection in living cells. Nucleic acids research. 
2004;32(6):e58. 
53. Santangelo P, Nitin N, Bao G. Nanostructured probes for RNA detection in living cells. 
Ann Biomed Eng. 2006;34(1):39-50. 
54. Rhee WJ, Bao G. Simultaneous detection of mRNA and protein stem cell markers in live 
cells. BMC Biotechnol. 2009;9:30. 
55. Ban K, Wile B, Kim S, Park HJ, Byun J, Cho KW. Purification of cardiomyocytes from 
differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific 
mRNA. Circulation. 2013;128(17):1897-909. 
56. Ban K, Wile B, Cho KW, Kim S, Song MK, Kim SY. Non-genetic Purification of 
Ventricular Cardiomyocytes from Differentiating Embryonic Stem Cells through Molecular 
Beacons Targeting IRX-4. Stem cell reports. 2015;5(6):1239-49. 
57. Wile BM, Ban K, Yoon YS, Bao G. Molecular beacon-enabled purification of living cells 
by targeting cell type-specific mRNAs. Nature protocols. 2014;9(10):2411-24. 
58. Jha R, Wile B, Wu Q, Morris AH, Maher KO, Wagner MB, et al. Molecular beacon-based 
detection and isolation of working-type cardiomyocytes derived from human pluripotent stem 
cells. Biomaterials. 2015;50:176-85. 
59. Ehler E, Moore-Morris T, Lange S. Isolation and culture of neonatal mouse 
cardiomyocytes. Journal of visualized experiments : JoVE. 2013(79). 
60. Zhang Y, Cao N, Huang Y, Spencer CI, Fu JD, Yu C. Expandable Cardiovascular 
Progenitor Cells Reprogrammed from Fibroblasts. Cell Stem Cell. 2016;18(3):368-81. 
61. Li XH, Li Q, Jiang L, Deng C, Liu Z, Fu Y. Generation of Functional Human Cardiac 
Progenitor Cells by High-Efficiency Protein Transduction. Stem cells translational medicine. 
2015;4(12):1415-24. 
62. Goumans MJ, de Boer TP, Smits AM, van Laake LW, van Vliet P, Metz CH. TGF-beta1 
induces efficient differentiation of human cardiomyocyte progenitor cells into functional 




63. Schubert M, Lindgreen S, Orlando L. AdapterRemoval v2: rapid adapter trimming, 
identification, and read merging. BMC Res Notes. 2016;9:88. 
64. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate 
alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome 
biology. 2013;14(4):R36. 
65. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 
2012;9(4):357-9. 
66. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for 
RNA-seq data with DESeq2. Genome biology. 2014;15(12):550. 
67. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA. Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide expression 
profiles. Proceedings of the National Academy of Sciences of the United States of America. 
2005;102(43):15545-50. 
68. Becker M, Maring JA, Oberwallner B, Kappler B, Klein O, Falk V. Processing of Human 
Cardiac Tissue Toward Extracellular Matrix Self-assembling Hydrogel for In Vitro and In Vivo 
Applications. J Vis Exp. 2017(130). 
69. Becker M, Maring JA, Schneider M, Herrera Martin AX, Seifert M, Klein O. Towards a 
Novel Patch Material for Cardiac Applications: Tissue-Specific Extracellular Matrix Introduces 
Essential Key Features to Decellularized Amniotic Membrane. Int J Mol Sci. 2018;19(4). 
70. Qian L, Berry EC, Fu JD, Ieda M, Srivastava D. Reprogramming of mouse fibroblasts into 
cardiomyocyte-like cells in vitro. Nature protocols. 2013;8(6):1204-15. 
71. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give 
rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Developmental cell. 
2006;11(5):723-32. 
72. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M. Human 
cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. 
Nature. 2008;453(7194):524-8. 
73. Bondue A, Lapouge G, Paulissen C, Semeraro C, Iacovino M, Kyba M. Mesp1 acts as a 
master regulator of multipotent cardiovascular progenitor specification. Cell stem cell. 
2008;3(1):69-84. 
74. Cai CL, Liang X, Shi Y, Chu PH, Pfaff SL, Chen J. Isl1 identifies a cardiac progenitor 
population that proliferates prior to differentiation and contributes a majority of cells to the heart. 




75. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y. Cardiac progenitor 
cells from adult myocardium: homing, differentiation, and fusion after infarction. Proceedings of 
the National Academy of Sciences of the United States of America. 2003;100(21):12313-8. 
76. Wu SM, Fujiwara Y, Cibulsky SM, Clapham DE, Lien CL, Schultheiss TM. 
Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the 
mammalian heart. Cell. 2006;127(6):1137-50. 
77. Cao N, Liu Z, Chen Z, Wang J, Chen T, Zhao X. Ascorbic acid enhances the cardiac 
differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac 
progenitor cells. Cell research. 2012;22(1):219-36. 
78. Lalit PA, Rodriguez AM, Downs KM, Kamp TJ. Generation of multipotent induced cardiac 
progenitor cells from mouse fibroblasts and potency testing in ex vivo mouse embryos. Nature 
protocols. 2017;12(5):1029-54. 
79. Smits AM, van Laake LW, den Ouden K, Schreurs C, Szuhai K, van Echteld CJ. Human 
cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse 
myocardium. Cardiovascular research. 2009;83(3):527-35. 
80. Naito AT, Shiojima I, Akazawa H, Hidaka K, Morisaki T, Kikuchi A. Developmental 
stage-specific biphasic roles of Wnt/beta-catenin signaling in cardiomyogenesis and 
hematopoiesis. Proceedings of the National Academy of Sciences of the United States of America. 
2006;103(52):19812-7. 
81. Sia J, Yu P, Srivastava D, Li S. Effect of biophysical cues on reprogramming to 
cardiomyocytes. Biomaterials. 2016;103:1-11. 
82. Li Y, Dal-Pra S, Mirotsou M, Jayawardena TM, Hodgkinson CP, Bursac N. Tissue-
engineered 3-dimensional (3D) microenvironment enhances the direct reprogramming of 
fibroblasts into cardiomyocytes by microRNAs. Scientific reports. 2016;6:38815. 
83. Oberwallner B, Brodarac A, Anic P, Saric T, Wassilew K, Neef K. Human cardiac 
extracellular matrix supports myocardial lineage commitment of pluripotent stem cells. European 
journal of cardio-thoracic surgery : official journal of the European Association for Cardio-
thoracic Surgery. 2015;47(3):416-25; discussion 25. 
84. Lam JT, Moretti A, Laugwitz KL. Multipotent progenitor cells in regenerative 
cardiovascular medicine. Pediatr Cardiol. 2009;30(5):690-8. 
85. Chen JX, Krane M, Deutsch MA, Wang L, Rav-Acha M, Gregoire S. Inefficient 





86. Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T. Induction of 
cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circulation 
research. 2012;111(9):1147-56. 
87. Mathison M, Singh VP, Gersch RP, Ramirez MO, Cooney A, Kaminsky SM. "Triplet" 
polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular 
functional improvement compared with singlet vectors. The Journal of thoracic and cardiovascular 
surgery. 2014. 
88. Mohamed TM, Stone NR, Berry EC, Radzinsky E, Huang Y, Pratt K. Chemical 




                  
13.  STATUTORY DECLARATION   
 
I, Dipthi Bachamanda Somesh, by personally signing this document in lieu of an oath, hereby 
affirm that I prepared the submitted dissertation on the topic “Induced cardiomyocyte precursor 
cells obtained by direct reprogramming of cardiac fibroblasts”, independently and without the 
support of third parties, and that I used no other sources and aids than those stated. 
All parts, which are based on the publications or presentations of other authors, either in letter or 
in spirit, are specified as such in accordance with the citing guidelines. The sections on 
methodology (in particular regarding practical work, laboratory regulations, statistical processing) 
and results (in particular regarding figures, charts and tables) are exclusively my responsibility. 
 
My contributions to any publications to this dissertation correspond to those stated in the below 
joint declaration made together with the supervisor. All publications created within the scope of 
the dissertation comply with the guidelines of the ICMJE (International Committee of Medical 
Journal Editors; www.icmje.org) on authorship. In addition, I declare that I am aware of the 
regulations of Charité – Universitätsmedizin Berlin on ensuring good scientific practice and that I 
commit to comply with these regulations.  
 
The significance of this statutory declaration and the consequences of a false statutory declaration 
under criminal law (Sections 156, 161 of the German Criminal Code) are known to me.” 
 
 













14. DECLARATION OF YOUR OWN CONTRIBUTION TO ANY PUBLICATIONS 
 
Dipthi Bachamanda Somesh contributed to the Abstract publications listed below: 
 
D Bachamanda Somesh, K Klose, JA Maring, K Juerchott, U Krueger, D Kunkel, A Kurtz, V 
Falk, M Gossen, C Stamm  
Generating proliferative induced cardiomyocyte precursor cells 
EMJ Cardiology 2019 
O. Reidell, D. B. Somesh, K. Klose, S. Protze, D. Kunkel, U. Krüger, K. Jürchott, V. Falk, M. 
Gossen, C. Stamm 
Maturation of Induced Cardiomyocyte Precursor Cells Created by Direct Reprogramming 
In: Thorac cardiovasc Surg 2018; 66(S 01): S1-S110 
DOI: 10.1055/s-0038-1627947 
Somesh DB, Klose K, Kunkel D, Krüger U, Protze S, Falk V, Gossen M, Stamm C  
Induced cardiomyocyte progenitor cells created by direct reprogramming and 
transcriptional selection 
In: Clin Res Cardiol 106, Suppl 1, April 2017-P475.  
DOI: 10.1007/s00392-017-1105-2 
D.B. Somesh, K. Klose, S. Protze, D. Kunkel, U. Krüger, K. Jürchott, M. Gossen, V. Falk, C. 
Stamm 
Next generation sequencing reveals a committed but immature phenotype of induced 
cardiomyopcyte progenitor cells 
In: Thorac cardiovasc Surg 2017; 65(S 01): S1-S110 
DOI: 10.1055/s-0037-1598858 
D.B. Somesh, K. Klose, S. Protze, D. Kunkel, U. Krüger, K. Jürchott, M. Gossen, V. Falk,        
C. Stamm 
Maintenance and expansion of induced cardiomyocyte precursor cells created by direct 
reprogramming 
In: Thorac cardiovasc Surg 2017; 65(S 01): S1-S110 
DOI: 10.1055/s-0037-1598945 
D.Somesh, K.Klose, S.Protze, D.Kunkel, V.Falk, M.Gossen, C.Stamm  
118 
 
Transcriptional selection and maintenance of induced cardiomyocyte precursor cells 
created by direct reprogramming  
Submitted to:  XLIII Annual Congress of the European Society for Artificial Organs 2016 
(ESAO Congress 2016) 
D.Somesh, K.Klose, S.Protze, D.Kunkel, A.Kurtz, V.Falk, Y.H.Choi, M.Gossen, C.Stamm  
Transcriptional selection of induced cardiomyocyte precursor cells 
In: The Thoracic and Cardiovascular Surgeon 64(S 01) · January 2016 
DOI: 10.1055/s-0036-1571714 
D. Bachamanda-Somesh, K. Klose, S. Protze, A. Kurtz, M. Gossen, C. Stamm 
Direct in vitro lineage reprogramming of murine fibroblasts into cardiomyocytes induces 
cell death 
In: The Thoracic and Cardiovascular Surgeon 62(S 01) · February 2014 
DOI: 10.1055/s-0034-1367447 
 
Contribution - Study design, performing the experiments, animal experiments, data analysis, 












Signature of doctoral candidate 
 119 
15.      CV  
 
 
For reasons of data protection law, my curriculum vitae will not be published in the 








For reasons of data protection law, my curriculum vitae will not be published in the 







For reasons of data protection law, my curriculum vitae will not be published in the 





16. ACKNOWLEDGEMENT  
 
Marie Curie warned that “The way of progress is neither swift nor easy”. The true difficulty of a graduate 
school lies in the mental challenge that extends beyond the intellectual and into the psychological. The only 
thing swift and easy about science is how quickly everything call fall apart. In the lab, you work hard, work 
early, work late, work weekends and still fail.  No one warns us how it feels to fail constantly.  
However, as many times as I was knocked down, I have been able to stand up, brush off my lab coats and 
keep pipetting, because of all the support I got from my family, friends, lab mates, and supervisors.  
 
I am grateful for my supervisors Prof. Dr. Christof Stamm, Prof. Andreas Kurtz, and Dr. Manfred Gossen, 
without whom this project would not have been.  They made this project what it is. I am lucky to have had 
them to guide and support me with remarkable expertise and assistance with objective insights and answers 
to my questions and troubles. Special thanks to Christof Stamm, for giving me the opportunity to pursue 
my Ph.D. research under his guidance. He gave me all the freedom to pursue my research and silently 
steered me in the right direction whenever he thought I needed it. An extended thanks to Dr. Manfred 
Gossen for always having his office door open for guidance with research and writing this thesis.  
 
I am very grateful to the Berlin Brandenburg School for Regenerative Therapies (BSRT) for allowing me 
to be a part of the prestigious graduate school. I am also thankful for all the funding bodies, without which 
I would not have been able to pursue my PhD research. 
 
Special gratitude to the following staff of the institute for their gracious help and assistance: Dr. rer. nat. 
Désiree Kunkel, of the BCRT FACS core facility, Ulrike Krüger of the BIH core facility Genomics, and 
Dr. rer. nat. Karsten Jürchott, Bioinformatician of Development & Exploratory Lab (DEL).  
 
I would also like to acknowledge all my scientific colleagues Rajika Roy, Kristin Klose, Andreas Bader, 
Zhiyi Xu (Daisy), Barbara Oberwallner, Matthias Becker, Ana Gracia Duran, Liu Zihou, Donald Hanssen, 
Timo Nazari, Sebastian Neuber and Olivia Reidell for the regular progress meetings, journal clubs, all the 
fruitful discussions, the lunch breaks, cake sessions and all the little things we did to make PhD life fun.  
Special thanks to our post doc Dr. Janita Aline Maring, for performing all animal surgeries and teaching in 
the process. It was a fantastic experience to assist with animal surgeries.  
 
A very special thanks to Kris for being there at every step of my Ph.D. work and for helping me in myriad 
different ways. I am grateful for all our long coffee break conversations. Every PhD student should be so 





My acknowledgement would be incomplete without thanking my family. This journey would have not been 
possible without their support and encouragement.  
 
I am very thankful to my mom, dad, and Jagjith for their unending love and support. They let me be and do 
what I want and kept me going on my path to success.  
 
Thanks to Achen, Amma, Sandhya, Shreejith, and my adorable little niece Naina for their support and 
patience along the way.  
 
I am grateful to Sreesanth for being the moral and emotional support in my life, for making sure there 
wasn’t a dull day, and for always being there. I thank him for putting up with me in difficult moments where 
I felt stumped and for goading me on to follow my dream of getting this degree. Without his unwavering 
love, support, and belief in me I never would have made it this far. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
